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Abstract  
Diphenylalanine (FF) peptide is the core-recognition motif of β-amyloid 
polypeptide, a peptide associated with diseases such as AlzheimerÕs and which 
is known to be capable of self-assembly. FF has attracted interest in 
nanotechnology due to the physical and chemical stability and mechanical 
rigidity of the self-assembled nanotube form of the peptide. A number of 
promising applications of FF nanotubes have previously been explored. To 
extend this work to biomedical and pharmaceutical areas, an improved 
understanding of the physicochemical properties of FF tubes, together with the 
influence of assembly conditions, cytotoxicity properties and potential in drug 
delivery field are presented in this thesis. 
The studies presented in Chapter 2 address the self-assembly of FF peptide 
prepared by two known methods of preparation, one aqueous based, the other 
utilizing an organic solvent. A range of complementary characterization 
methods is applied including atomic force microscopy, scanning electron 
microscopy, focused ion beam-scanning electron microscopy, X-ray powder 
diffraction, and Raman Spectroscopy. The investigations reveal differences in 
morphology of the tubes formed by the different preparation methods. The 
aqueous based method produces tubes that are long, straight and unbranched 
and are consistent with previous work. The alternative organic solvent method 
produced tubes that are shorter and narrower. In addition, these tubes displayed 
flexibility and nucleation points. Following on from these findings, a proposed 
mechanism of tube growth is discussed. 
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Chapter 3 further extends the investigation to the biological field. Possible 
cytotoxicity issues are studied using a MTT assay on a HeLa cell line. 
Moreover, total internal reflection microscopy was applied to investigate HeLa 
cell behaviour in the presence of FF nanotubes. The results from these studies 
reveal that the nanotubes and FF peptide do not cause any mitochondrial 
related damage to HeLa cells. Furthermore, short tubes were observed to be 
taken up by cells through a suggested macropinocytosis pathway. 
Finally, in Chapter 4 the focus turns to the investigation of the potential of FF 
tubes as drug carriers in drug delivery. Here, successful synthesis of drug-
loaded FF tubes is presented with two model drugs. The physical 
characterization of the complex formed under different conditions using 
scanning electron microscopy reveals FF nanotube self-assembly is a drug 
concentration and solvent type dependent process. Finally, in vitro drug release 
from FF nanotubes is performed and compared to that of the drug alone. 
Extended drug release is observed for both drug candidates and release 
mechanisms are proposed. 
The results presented throughout this thesis demonstrate the versatility of self-
assembling FF peptides for the formation of tubular nanostructures with 
different morphologies and physical properties under different conditions. The 
assembled nanostructures appear non-toxic to cells and offer promise in drug 
delivery as novel drug carriers. 
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Chapter 1 Introduction  
 
1.1 Protein folding and misfolding 
Proteins serve important functions in our life; they are among the most 
important molecules in living organisms and are crucial to the maintenance of 
life. There are more than a million different proteins in our body and over half 
the dry weight of a cell is comprised of proteins [1, 2]. They take part in almost 
every chemical process that occurs within our body and have always attracted 
interest in research and investigation.  
Proteins are made up of amino acids linked by peptide bonds [3]. There are 20 
naturally occurring amino acids. The sequence which these amino acids occur 
within the polypeptide chain is referred to as the primary structure of a protein. 
The secondary structure of a protein is referred to the localized organization of 
the polypeptide chain; different spatial arrangements such as α-helices or β-
sheet structures are formed as a result of hydrogen bonds between the side 
chains of the amino acids. These secondary elements further arrange 
themselves to create functionalized domains which are referred to as the 
tertiary structure of a protein. All of the domains are held together by ionic, 
disulfide and salt bridges and other non-covalent interactions such as van der 
Waals forces between different amino acid residues. For the majority of 
proteins that are comprised of more than two polypeptide chains, the final level 
of structural organisation is the quaternary structure which is completed by the 
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assembly of each subunit into a functionalized final structure (Figure 1-1) [3]. 
The secondary and tertiary structural elements of proteins are various and 
adopt different orientations and combinations, which then self-assemble into 
intricate 3D structures. Ultimately this is based on the primary amino acid 
sequence, which has been selected to achieve a certain function through 
evolutionary pressure [4-6]. 
 
 
 
 
Figure 1- 1 Protein structures. (a) The amino acid sequence of a protein is referred to 
as the primary structure; (b) different units of the sequence form the secondary 
structures via hydrogen bonding between residues of the amino acids presented in the 
sequence; (c) these elements further arrange themselves into tertiary structure that is 
stabilized by ionic, disulfide and salt bridges and other non-covalent interactions; (d) 
quaternary structure of a protein is completed by assembly of each polypeptide chains 
into a functionalized final structure [5].  
 
1.1.1 Underlying mechanism of protein folding 
Protein folding is a complex process still far from fully understood. There are 
20 naturally occurring amino acids hence the total possible number of primary 
sequences is extremely large. Moreover, there are various secondary structures 
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with different orientations and combinations. All these elements self-recognise 
and fold into the final complex structure with specific functions within 
milliseconds. One may question how such a complex structure can be created 
from numerous possible elements and combinations within such a short 
amount of time. Indeed, Levinthal proposed this question in 1968 which is 
known as LevinthalÕs paradox, which states that it is impossible for a protein to 
adopt all possible conformations in such a short time in search for the correct 
fold [6]. This paradox was solved recently evidenced upon a large number of 
experimental and theoretical studies, and the proposal of the energy landscape 
theory [7-12]. It is now believed that protein folding process is a Ôrandom 
searchÕ rather than a restricted pathway; each possible conformation accessible 
to a polypeptide chain is included in the searching process and the search is 
based on the entropy, enthalpy and free energy of each available conformation. 
The search is made possible because the native conformation is, in general, 
more stable and requires less energy than the non-native states [13-15]. This 
description of protein folding is referred to as the Ônew viewÕ of the protein 
folding process [16]. The conceptual basis of this approach is shown in Figure 
1-2. In general, each possible conformation of a protein is associated with a 
specific free energy. Plotting free energies against the corresponding 
conformations generates an energy landscape and the resultant Ôfunnel shapeÕ 
leads to the final correct conformation, ensuring the number of conformations 
accessible to a polypeptide chain is always reduced as the search approaches 
the native state [2, 16]. During folding, proteins, especially ones with large 
numbers of amino acid residues, often form intermediate states; the native state 
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is the most stable formation thus enthalpy favoured which compensates the 
decreased entropy as a result of the reduced disorderness of the native state [2, 
16]. 
An earlier model that describes the mechanism of protein folding was proposed 
by Fersht, and is known as the Ônucleation-condensationÕ model [11, 17, 18]. 
This model proposes that during the folding process, a folding nucleus of a 
small number of key residues forms first, followed by the spontaneous 
formation of secondary and tertiary structures as the whole protein condenses 
around the nucleus.   
Proteins are synthesized inside of ribosome within cells. Few proteins fold 
spontaneously in a co-translational manner whilst a nascent chain is still 
attached to the ribosome [19, 20]. The majority of protein folding undergoes a 
much more complex route, which occurs in the cytoplasm or endoplasmic 
reticulum [21]. Considering the crowded environment in the cell, where the 
concentration of macromolecules can reach 400 mg/ml [22], newly synthesized 
polypeptide chains can easily interact with surrounding cellular components 
and result in misfolding in this environment. To prevent this from occurring, 
cells have a number of strategies, one of them being the molecular chaperones 
[23-27]. 
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Figure 1- 2 Energy landscape for the folding of lysozyme which has 129 residues and 
consisting of two domains, denoted as α or β. The free energy (F) is represented as a 
function of the number of possible conformation (Qα and Qβ). The schematic energy 
landscape has a Ôfunnel-likeÕ shape that ensuring the efficiency of folding [16].  
 
The function of molecular chaperones is to bind to polypeptide chains at the 
regions that are not normally present in the final structure e.g. unwanted 
backbone parts, thereby maintaining them in a folding competent 
conformation, shielding them from their surroundings [28]. For proteins that 
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have misfolded, cytosolic enzymes recognise and tag them with ubiquitin  
molecules, from where they undergo further assembly in the assist of 
proteasome to be degraded [29, 30].  
 
1.1.2 Protein misfolding and diseases 
Despite the natural defence mechanisms that prevent proteins from misfolding, 
there are a large number of diseases caused by, or related to, the abnormal 
folding of proteins [2, 31-44]. The causes of protein misfolding are diverse; for 
example, it can be triggered by mistranslation [45], mistranscription [46] or 
gene mutation [47], which all lead to the disturbance of the primary sequence 
of the protein. Alternatively errors could occur after protein synthesis is 
completed; changes of surrounding conditions such as pH or temperature could 
cause destabilization of protein, resulting in misfolding or unfolding [48-50]. 
Failure to fold correctly will give rise to the malfunctioning of proteins and 
possibly lead to disease [34, 37, 51, 52]. Alternatively, misfolded proteins can 
create intractable aggregations which are related to a number of diseases, for 
instance, AlzheimerÕs and ParkinsonÕs diseases [35, 53]. Some of the diseases 
associated with protein misfolding are presented in Table 1.1.  
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                          Table 1. 1 Representative protein folding diseases [53]. 
Disease Protein Site of folding 
Hypercholesterolemia 
Low-density lipoprotein 
receptor 
ER 
Cystic fibrosis 
Cystic fibrosis trans-
membrane regulator 
ER 
Phenylketonuria Phenylalanine hydroxylase Cytosol 
HuntingtonÕs disease Huntington Cytosol 
Marfan syndrome Fibrillin ER 
Osteogenesis imperfecta Procollagen ER 
Sickle cell anaemia Haemoglobin Cytosol 
α1-Antitrypsin deficiency α1-Antitrypsin ER 
Tay-Sachs disease β-Hexosaminidase ER 
Scurvy Collagen ER 
AlzheimerÕs disease Amyloid β-peptide/tau ER 
ParkinsonÕs disease α-Synuclein Cytosol 
Scrapie/Creutzfeldt-Jakob 
disease 
Prion protein ER 
Familial amyloidoses Transthyretin/Lysozyme ER 
Retinitis pigmentosa Rhodopsin ER 
Cataracts Crystallins Cytosol 
Cancer P53 Cytosol 
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1.1.3 Amyloid fibril formation 
It is known that a number of diseases caused by protein misfolding are 
associated with the occurrence of protein aggregations called amyloid fibrils 
[32, 54, 55]. Examples include AlzheimerÕs disease that is associated with 
amyloid β-peptide [56-60], type II diabetes which is associated with the islet 
amyloid polypeptide [61-63], and Creutzfeldt-Jakob disease that is associated 
with prion protein [64, 65] (some of these diseases are shown in Table 1.1). 
These stable, insoluble aggregates are very resistant to protease degradation 
and share similar morphology but not necessarily obvious gene sequences [66]. 
The common structure of amyloid fibrils is usually made up of 2-6 
protofilaments (i.e. the fibrillar subunits) that twist around each other with an 
overall diameter of few nanometres in width and a few micrometres in length 
suggesting that amyloid fibrils might be a generic conformation that all 
proteins could adopt (Figure 1-3) [67]. Furthermore, it is now suggested that 
amyloid fibrils may be the consequence of the pathological changes related to 
disease state, rather than the cause of the associated diseases [66]. Indeed, there 
are examples of proteins or polymers that can form amyloid fibrils that share 
common morphology and display similar properties in vitro, examples include 
myoglobin [68] and polylysine [69], and short peptides taken from the 
sequence of amyloid polypeptides [70]. These proteins follow a nucleation-
dependent process just like the rest of amyloid fibrils formations. The 
aggregation is most likely to occur from partially folded intermediates, and is 
characterized by a critical concentration below which no aggregation will 
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occur, followed by a lag phase then a period of rapid growth, and eventually a 
steady state phase where monomers are in equilibrium with fibrils [71, 72].  
 
 
 
 
 
 
 
 
Figure 1- 3 A molecular model generated from cryo-EM analysis of an amyloid fibril 
grown from an SH3 domain. Figure 1-3a is a representation of an overview of the 
fibril structure; four twisted protofilaments are shown in blue. Figure 1-3b represents 
the side view of a single protofilament. Figure 1-3c represents the cross-section of the 
fibril and Figure 1-3d is a slightly tilted side view of the fibril. The outer surface of the 
fibril is shown in green and the direction of the βÐsheet packing is shown by the blue 
arrows [67].  
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1.2 Molecular self-assembly into various diphenylalanine-based 
nanostructures 
 
As mentioned above, the ability to form amyloid fibrils appears general; there 
are various investigations of short peptide fragments taken from parent 
amyloid proteins that undergo self-assembly in mild in vitro conditions into 
amyloid-like nanofibrils [73-75]. One study that investigated the minimal 
amyloidogenic fragments within β-amyloid polypeptide led to the discovery 
that the short dipeptide, diphenylalanine (FF) could self-assemble [76]. It is 
now known that this core-recognition motif of β-amyloid polypeptide rapidly 
self-assembles into discrete tubular nanostructures that retain many 
characteristics of amyloid fibrils formed by the parent polypeptide, for 
instance, birefringence in polarized light with Congo red staining and β-sheets 
conformation [77, 78]. 
Since the emergence of FF as the simplest self-assembling building blocks, 
many studies have been carried out to investigate the physical and chemical 
properties of FF and its self-assemblies [79-82]. The nanostructures formed by 
FF peptide are diverse ranging from nanotubes and nanorods to spherical 
vesicles [83]. A summary of various FF nanostructures and their potential 
applications is presented in Figure 1-4. For each type of nanostructure a 
detailed review of its chemical and physical characteristics, together with its 
previous studies and potential applications will be discussed later. 
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Figure 1- 4 Schematic representation of various nanostructures formed by 
diphenylalanine-based peptide building blocks and their potential applications.  
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1.2.1 FF-based nanotubes 
Reches and Gazit have shown that FF, like the complete β-amyloid sequence, 
can undergo rapid self-assembly in mild in vitro conditions [84]. The nano- and 
micro- structures formed have been studied by a range of techniques, including 
atomic force microscopy (AFM) [79, 81, 85], scanning electronic microscopy 
(SEM) [86, 87] and transmission electronic microscopy (TEM) [79, 88]. These 
studies have shown that the assembled FF adopts a hollow tubular structure, 
with open ends. The diameters of such tubes vary from around 50 to 2000 nm 
depending primarily upon the original concentration of the peptide [89]. FF 
tubes are long on the nanoscale, discrete and unbranched, with a persistence 
length up to hundreds of microns, and a YoungÕs modulus of approximately 19 
GPa [78]. The mechanical stiffness of FF tubes is comparably higher than other 
biological materials, such as amyloid fibrils formed from protein insulin 
(YoungÕs modulus = 3.3 GPa) [90] and other synthetic polypeptides (e.g. 
amyloid fibrils self-assembled from poly-Val-Gly-Gly-Leu-Gly have a 
YoungÕs modulus in the range from 3.5-7MPa) [91]. FF tubes also display 
remarkable thermal stability up to 90 ¡C; the tube structural integrity is lost and 
phenylalanine released at temperature above 150 ¡C [79, 92, 93]. Moreover, 
the chemical stability of FF nanotubes in various organic solutions has also 
been investigated revealing that FF nanotubes have outstanding chemical 
stability. One such study investigated FF nanotube solutions mixed with 
various organic solutions including ethanol, methanol, isopropanol, acetone 
and acetonitrile for half an hour, and then the incubated solutions were air-
dried and investigated with SEM analysis to reveal the assembled tubes, 
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showing the stability of FF nanotubes in these solvents [79]. Furthermore, the 
stability of FF nanotubes submerged in acetone and acetonitrile for half an 
hour was also investigated using SEM analysis, where again the FF tubes 
retained their structure [79]. Taken together, these remarkable properties have 
made FF nanotubes among the stiffest biological materials presently known, 
enabling the potential of FF nanotubes for nano-fabrication applications. 
There are two methods of FF nanotube preparation published to date, one 
established by GazitÕs group [76], and the other reported by SongÕs group [89]. 
The former method of preparation involves dissolving FF peptide (L-Phe-L-
Phe) in an organic solvent, 1,1,1,3,3,3- hexafluoropropan-2-ol (HFIP), 
followed by dilution with water. Another preparation omits HFIP by heating 
FF peptide (D-Phe-D-Phe) at 65¡C in water for thirty minutes and the solution 
was then cooled to room temperature. The latter preparation avoids the toxic 
HFIP which is known to be extremely destructive to tissues of the mucous 
membrane, upper respiratory tract and eyes [94], thus making this approach 
more attractive for the potential development of FF nanotubes as drug delivery 
systems and other in vivo applications. AFM and SEM visualization of these 
nanotubes show no apparent difference in morphology from those prepared in a 
HFIP/water mixture, although they exhibit slightly larger diameters (ranging 
from 400-2000 nm) [89].  
GazitÕs group investigated the rationale behind the process of molecular self-
assembling of FF, they hypothesized that the dipeptides are linked via 
hydrogen bonding to cause one-dimensional propagation. The resultant 
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intersheet stacking interaction between aromatic groups of FF provides an 
energetic contribution to forming the extended β-sheet, i.e. a two-dimensional 
layer. The final overall tubular structure is accomplished by closure of the 
extended sheet along one axis of the 2D layer (Figure 1-5) [83].  
 
 
 
Figure 1- 5 Model for the assembly of the diphenylalanine nanotube. Extended β-sheet 
is formed as a result of π-π stacking interactions between the aromatic groups of FF 
molecules, a closure of the sheet gives the final tubular structure that is further 
stabilized by H- bonding and aromatic interactions.  
This hypothesis is consistent with previous evidence found by MakinÕs group, 
where they suggested the importance of phenylalanine groups in amyloid fibril 
formation by means of π-π stacking interactions [95]. The molecular packing 
of FF nanotubes was further investigated by Gorbitz. His group found that FF 
nanotubes have chiral hydrophilic channels composed of 6 numbers of peptide 
per turn with a van der WaalÕs diameter up to 10 (Figure 1-6) [96]. Water 
molecules stay well ordered in the hydrophilic channels [96-98]. This finding 
is consistent with previous result from SongÕs group, which they have found 
there were parallel channels running in the direction of the FF tube axis [89]. 
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Figure 1- 6 Molecular packing arrangement of diphenylalanine nanotubes. The unit 
cell and molecular packing of FF tube was presented in 1-6a showing each unit 
composed of 6-FF molecules with peptide backbones arranged in the centre and 
hydrophobic aromatic rings oriented outside. Small spheres represent water molecule 
positions. A single channel view from the top is presented in 1-6b, and a side-view of 
the channel is presented in 1-6c. Purple clusters represent water molecules that stay 
in the centre of the channel [96].  
 
Many efforts have been applied to achieve ordered spacial organization of self-
assembled FF nanotubes. Several strategies have been developed to achieve 
both vertical and horizontal alignment of FF tubes [80, 99-103]. Vertically 
aligned ÔnanoforestsÕ by axial unidirectional growth of FF peptide tubes was 
achieved by a vapour deposition method [99]. FF peptide powder was heated to 
220 ¡C and at this temperature FF molecule altered the chemical structure from 
liner to cyclic, cyclo (-Phe-Phe). The subsequent assembly was achieved on a 
substrate placed above the peptide source to form the ordered vertical 
alignment of the FF nanotube array (Figure 1-7).  
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Figure 1- 7 Vertical alignment of diphenylalanine nanotubes. A schematic 
representation of the vapour deposition technique is shown in 1-7a; a representation 
of a single peptide nanotube is shown in 1-7b; the molecular arrangement of a unit 
cell composing 6 Cyclo-Phe-Phe molecules is presented in 1-7c and a typical SEM 
image of the vertically aligned nanoforest (side-view) is presented in 1-7d [99].  
 
In another study, vertical alignment was achieved by using a FF peptide thin 
film as a template to grow tubes [102]. FF peptide was dissolved in HFIP in the 
complete absence of water to produce an amorphous peptide thin film first; the 
film then acted as a template under the proper amount of water vapour or high 
thermal energy (above 100 ¡C) to grow FF nanorods (nanorods were used to 
describe the assembled nanostructures rather than nanotubes as these 
assemblies were solid inside under SEM) (Figure 1-8). The powder X-ray 
diffraction pattern of the native FF nanotubes was also different from that of 
the FF nanorods, indicating a change in the crystal structure of the nanorods. 
Time-of-flight secondary ion spectroscopy and high-performance liquid 
chromatography have shown the presence of cyclo (-Phe-Phe), instead of the 
linear H-Phe-Phe-OH in the assembled aligned structure. This finding is in 
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good agreement with the former study which also pointed out the change of FF 
structure from liner to cyclic [99]. Furthermore, horizontal alignment of FF 
nanotubes has also been demonstrated by coating ferrofluid on the surface of 
nanotubes or exposing them to a strong magnetic field without any additional 
treatment [104].  
 
 
 
 
 
 
 
 
Figure 1- 8 Vertical alignment of diphenylalanine nanorods from a peptide thin film. 
SEM micrographs are presented from A to D with schematics representing the effect 
of water on the formation of ordered peptide nanorods. Starting from the right: (A) 
Amorphous dipeptide film was formed by placing a drop of FF dissolved in HFIP on 
solid substrate and allowing to evaporate in the absence of water; (B) formation of 
discrete nuclei was achieved after water vapour treatment; (C) unidirectional growth 
of FF nanorods from nuclei after further water vapour exposure; (D) high-resolution 
SEM image of FF nanorods [102].  
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1.2.2 Phase transition of diphenylalanine from nanotubes to 
nanovesicles 
Interestingly, in the original work demonstrated by SongÕs group, spherical 
nanostructures were found together with nanotubes (Figure 1-9) [89]. They 
claimed that by further diluting one part of the nanotube solution with an equal 
volume of water, vesicles with diameters of a few hundred nanometres were 
observed. This finding has led to the suggestion that the concentration of the 
peptide is a key factor in the formation of the nanotubes and may play an 
important role in determining the morphology of the assemblies. Precise 
control of the shape and the size of the self-assembled nanostructures enables 
their applications in nanofabrication, therefore an understanding of the 
structural transition and the key factors that may influence the shape and the 
size of the final nano-assemblies are crucial.  
 
 
 
 
 
 
 
 
 
Figure 1- 9 SEM micrographs of (a) diphenylalanine nanotubes and (b) nanotubes 
mixed with nanovesicles [89].  
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There are a number of features that may affect the formation and the shape of 
FF nanotubes, including concentration of the peptide [105], solvent type [106, 
107], solvent pH [107], temperature [108], and chemical modification of the 
peptide [109]. Monomer-concentration-induced shape transition is found to be 
very common not only for FF, but other materials [110, 111]. For instance, the 
formation of micelles is critically dependent upon the concentration of the 
monomer, and micellization will only occur when the monomer concentration 
reaches a specific point, known as the critical micelle concentration. This is 
characteristic of all nucleation-dependent processes [112]. After the monomer 
critical concentration is reached, a lag phase when nucleus is formed from 
monomers occurs, followed by an elongation phase when tubes are growing 
out from the nucleus, and eventually to a steady state when monomers and 
nanotubes are at equilibrium. Li and co-workers have described the shape of 
the assemblies as dependent on three energy terms: the internal cohesion 
energy that compensates the decrease of entropy when random monomers 
(isotropic phase) form ordered nuclei (aggregation phase); the energy 
associated with the isotropic-aggregation interface; and the shape-dependent 
curvature elastic energy of the layer (i.e. the free energy cost related to other 
degrees of freedom of molecules in aggregation phase, for example, the 
orientation of growth of aggregations) [113]. Using these concepts they were 
able to define the critical tube-to-vesicle monomer concentration (CTVC) by 
the following expression (Equation 1.1): 
CTVC = CA e
-3γ/hC
A
k
B
T                                 (1.1) 
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Where CA is the molecule concentration of aggregation phase, γ is the surface 
tension constant of solution/aggregation interface, kB is the equilibrium 
constant, and T is temperature [113]. 
Solvent type, pH and concentrations are other important factors affecting the 
shape of self-assembled nanostructures [106]. A study conducted by ZhuÕs 
group revealed a structural transition from gel to flower-like microcrystal of an 
organogel self assembled from FF in toluene after introducing ethanol as a co-
solvent [106].  
Examples of temperature-driven phase transformation in self-assembled FF 
nanotubes have been described [99-103, 114]. A change was observed in the 
original molecular assembly of FF at 220 ¡C [99]  (100 ¡C [102] and 140 ¡C Ð 
150 ¡C [114] from other studies) from a linear peptide to a cyclic structure. 
The XRPD analysis indicated an irreversible phase transition of FF from a non-
centrosymmetric hexagonal space group to a centrosymmetric orthorhombic 
space group. 
Introducing chemical modification during FF tube assembly has been 
demonstrated to form closed-cage nanostructures [83]. After dissolving FF 
peptide in HFIP, 2-iminothiolane dissolved in dimethyl sulfoxide with 2% 
N,N-diisopropylethylamine was added to the solution and spherical 
nanostructures with diameters around a few hundred nanometres were 
observed. The transformation into spherical nanostructures was achieved upon 
complete closure of the extended β sheet (Figure 1-10). 
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Figure 1- 10 Schematic model of closely packed spherical nanostructure formation. 
Chemical modification of FF peptide of changing an amine to thiol introduces 
formation of closed-cage nanospheres. TEM micrographs of FF nanotubes and 
nanospheres formed by FF peptide that self-assembled in the presence of 2-
iminothilane are presented on the right [83]. 
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1.2.3 Nanowires 
A number of published works have been focused on FF-based nanowire 
production [76, 100, 115]. The synthesis of 1D FF nanowire can be achieved 
by dissolving the peptide in carbon disulfide solution, followed by 20 minutes 
sonication [116]. The formed nanowires exhibit liquid crystallinity with an 
average diameter of 346 nm and a length of 8.6 µm, and achieved rapid 
alignment under an external electric field (Figure 1-11a). Another study by 
Gazit et al. introduced ionic silver solution with the FF tube-forming solution, 
followed by addition of citric acid [76]. The reduced silver ions were observed 
to fill in the centre of FF tubes. Finally, the peptide mould was degraded by 
Proteinase K enzyme via proteolytic lysis. The formed silver nanowires had an 
average diameter of 20 nm observed by TEM, slightly narrower than the tubes 
as expected (Figure 1-11b). This work was further investigated by Gazit and 
his co-workers [115]. Recently, they reported the successful fabrication of 
coaxial FF nanocables: After silver-filled FF tubes were formed, a linker 
peptide containing the diphenylalanine motif (to enable π-π interaction with FF 
tube) and a cysteine residue (to provide a thiol group allowing further chemical 
modification) was added to bind the FF tube surface, the position of the linker 
was visualized by addition of gold nanoparticles which rapidly bind to the thiol 
group and distributed evenly on the tube surface. The binding and even 
distribution of the gold nanoparticles act as nucleation sites, enabling site-
specific initiation of electroless deposition of metal ions over the FF tube 
surface, thus forming silver-FF-metal coaxial nanowires (Figure 1-11c). 
Moreover, Ryu and co-workers published another method of nanowire 
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production with vertical alignment [103]. FF peptide was dissolved in HFIP to 
obtain a peptide thin film (as illustrated in Figure 1-8), polyaniline vapour was 
used instead of water vapour to promote vertical unidirectional growth of 
nanorods. From SEM analysis, polyaniline was clearly coated over the FF rods. 
This FF-polyaniline nanowire was then used as a template for synthesis of 
FF/CO3O4 composite nanowires [100, 101]. The formed FF/cobalt oxide 
hydrbid nanowires exhibit high stability against thermal, chemical and 
proteolytic attacks, demonstrating remarkable potential for energy storage 
(Figure 1-11d). In addition, Song et al. synthesized FF-nanotube platinum-
nanoparticle composites by simply mixing FF tube solution with K2PtCl4, 
followed by adding a reductant (ascorbic acid) solution [89]. A layer of Pt 
nanoparticles of 2-3 nm thickness was observed embedded in the FF tube walls 
under high resolution TEM (Figure 1-11e). A summary illustration of the 
above mentioned nanowire production approaches is presented in Figure 1-11. 
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Figure 1- 11 Schematic illustration of different methods of FF nanowire production 
[76, 89, 100, 115, 116].  
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1.2.4 Hydrogels 
Another type of nanostructure that FF peptide can self assemble into is a 
nanoscale-ordered hydrogel [117-120]. Compared with synthetic polymer-
based hydrogels, peptide-based ones are of great interest for tissue engineering 
and regeneration as they are expected to be biocompatible, easy degradable by 
proteolysis, very simple to chemically modify and to manufacture on a large 
scale, more over they are cost effective as well. FF is probably one of the 
smallest peptides that can self-assemble to form hydrogels [106, 121]. The 
procedure is very simple; gels were rapidly formed when FF peptide was 
dissolved in HFIP, followed with chloroform or toluene dilution. The formed 
gel has been demonstrated to encapsulate quantum dots and gold nanoparticles 
at room temperature (Figure 1-12). 
 
 
 
 
 
Figure 1- 12 Schematic of FF-hydrogel formation. FF peptides self-assemble via 
extensive π-π stacking interactions and hydrogen bonding to form nanofibrils. Such 
nanofibrils undergo further entanglement to form organogel [121]. 
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Another example of FF-based hydrogel uses FF with an α, β- 
dehydrophenylalanine residue (ΔPhe) [122]. The residue is an unsaturated 
analogue of phenylalanine that induces conformational constraints in the 
peptide backbone and also protects the dipeptide from proteolysis. The free 
termini of ΔPhe-FF offers potential gelation control by modulation of 
electrostatic interactions via further chemical modifications. The rapidly 
formed hydrogel was stimuli responsive to a number of external conditions 
such as pH, temperature and ionic strength. Encapsulation of bioactive 
molecules has been demonstrated and shown remarkable sustainable release. 
Moreover, the biocompatibility of the hydrogel has been confirmed with a 
MTT assay on HeLa and L929 cells [122].    
It has been demonstrated that an amine-modified analogue of FF, 9-
fluorenylmethoxycarbonyl (Fmoc)-FF, self-assembles into a nanoscale 
hydrogel with fibril diameters ranging from 10 to 100 nm in aqueous solution 
with physical characteristics of a gel (Figure 1-13) [118, 123-125]. The formed 
hydrogel is found to have stability over a wide range of temperature, pH range, 
and various solutions including urea, guanidinium hydrochloride and extreme 
acidic conditions. Rheology analysis of the Fmoc-FF hydrogel has shown a 
value of a storage modulus that is greater than the value of the loss modulus by 
one order of magnitude, which is a characteristic of a solid-like gel [118]. An 
MTT assay was performed on Fmoc-FF hydrogel exposed Chinese hamster 
ovary cells, showing >90% cell viability confirming its potential 
biocompatibility and as a scaffold for tissue engineering [123].  
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A number of spectroscopy techniques have been applied to study the 
intermolecular structure of FF-based hydrogels, including circular dichroism 
(CD) and fourier transform infrared (FTIR) [106, 121, 126], X-ray powder 
diffraction (XRPD) [121, 127], and fluorescence spectroscopy [128, 129]. CD 
analysis showed a wavelength of Fmoc-FF at 218 nm which is consistent with 
that of fluorescence spectroscopy a βÐsheet structure; FTIR spectrum of Fmoc-
FF showed two characteristic peaks of amide I band at 1630 and 1685 cm-1, 
which are in good agreement with an anti-parallel βÐsheet structure; the XRPD 
pattern showed a sharp peak at 2θ of 5.2¡ with d spacing of 1.7 nm, which 
corresponds to the thickness of a βÐsheet monolayer; furthermore, the 
fluorescence emission spectrum of Fmoc-FF was compared that of Fmoc-F, a 
shift of a peak from 320 to 330 nm was found, together with a new broad peak 
at 460 nm, which indicates the formation of excimer and higher order 
aggregates [118].  
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Figure 1- 13 Fmoc-FF hydrogel. The transparent, self-supporting hydrogel is 
presented in (a); rheology which confirms the solid-like property is shown in (b); light 
microscopy image of the hydrogel is presented in (c) and cryo-SEM micrograph is 
shown in (d) [118]. 
 
1.3 Application of diphenylalanine-based nanostructures 
FF and FF-based self-assembling nanostructures have demonstrated a broad 
range of applications in both non-biological [76, 100, 103, 116, 130] and 
biological fields [131, 132]. Their physical strength, chemical and thermal 
stability have made them of great interest in novel material synthesis such as 
nanowires [76], nanocables [115], nanosensors [133]; their proven 
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biocompatibility and ease for chemical modification offers potential as 
biosensor [131, 132, 134] and molecular scaffolds for tissue engineering [119, 
135-138]. The application of FF-based nanostructures in both nano-device 
fabrication and biological field will be summarized in following sections.   
 
1.3.1 Application for nano-device fabrication 
As mentioned earlier, FF is known as one of the shortest yet stiffest biological 
building block. The self-assembled nanotube presents remarkable physical and 
chemical characteristics which enable their applications in novel material 
synthesis, such as conductive nanowires [76], peptide-polymer coaxial 
nanocomposite [89, 100, 101], and nanocables [115]. A summary of current 
applications in nano-device fabrication is presented in Table 1.2. 
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    Table 1. 2 Summary of diphenylalanine nanostructures reported in the literature. 
Application Description Reference 
FF nanorods 
FF tube solution was mixed with CS2 to 
form conductive FF nanorods. 
[116] 
Silver nanowire 
FF tube solution was mixed with ionic 
silver solution, followed by adding sodium 
citrate and Proteinase K enzyme. 
[76] 
Silver-filled FF 
nanowire with metal 
ion tube surface 
decoration 
FF tube solution was mixed with ionic 
silver solution. A linker peptide solution 
was added followed by addition of gold 
ions 
[115] 
FF-polyaniline 
nanowire 
FF thin film was formed by dissolving FF 
peptide in HFIP without water dilution; 
vertical growth of Fr-based nanowire was 
formed by aniline vapour exposure at high 
temperature. 
[103] 
FF/polyaniline-cobalt 
oxide hydrbid 
nanocomposite 
FF/polyaniline-cobalt oxide hydrbid 
nanocomposite was formed by COCl2 and 
NaBH4 exposure to FF-polyaniline 
nanowire at room temperature. 
[100] 
FF nanotube platinum 
nanoparticle 
composites 
FF nanotube solution was added with 
K2PtCl4 and ascorbic acid 
[89] 
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1.3.2 Application in drug delivery and tissue engineering 
A number of studies have been focused on the potential applications of FF-
based nanostructures in the biological field. For example, FF and FF analogue-
formed hydrogels have proven ability to encapsulate nanocrystals and bioactive 
materials [120, 121, 126, 139]. The release of such bioactive material shows 
sustainable manner. The self-assembled hydrogels are easy to fabricate by a 
variety of methods and support cell growth of various cell lines [140, 141]. 
Furthermore, some of these hydrogels are responsive to enzyme and other 
stimuli, such as temperature and light [122]. Therefore enzymes can be used to 
control the formation of hydrogels, which normally take place in vivo; in other 
words, target-specific hydrogel formation might be possible. A number of 
natural enzymes, including thermolysin [142], β-lactamase [143], and 
phosphatase [144, 145], have been applied to the enzyme-tuned self-assembly 
of FF-based nanostructures. 
FF-based nanostructures possess potential for in vitro delivery of drugs and 
genes [146-148]. A recent study revealed a successful delivery of 
oligonucleotides to the interior of cells by a self-assembled FF analogue nano-
carrier. The cationic analogue of FF, H-Phe-Phe-NH2¥HCl, self-assembles into 
nanotubes and nanovesicles with further dilution at physiological pH. Confocal 
laser scanning microscopy confirmed the stable attachment of oligonucleotides 
via electrostatic interactions [146].  
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1.4 Thesis outline 
The aims of this PhD project are to investigate the self-assembly of 
diphenylalanine peptide utilizing a number of microscopy and spectroscopy 
techniques, including SEM, AFM, Raman spectroscopy, and XRPD, to study 
the morphology, intermolecular structure, self-assembly mechanism and other 
properties of FF peptide nanotubes; and to compare FF nanotubes prepared by 
different methods. To investigate the potential of the formed FF nanotubes as 
carriers for drug delivery purposes, selective drug molecules were incorporated 
into the FF structures and the subsequent in vitro drug release was performed.    
The first chapter of this thesis has presented a broad background of FF-based 
nanostrcutures. The physicochemical properties and biological properties of 
these nano-assemblies were introduced, together with the current and potential 
applications. 
The studies presented in Chapter 2 are focused on FF nanotubes. Although FF 
nanotubes are well studied by numerous investigations, there is no study which 
compares the properties of FF tubes prepared by different methods. This 
Chapter focuses on the characterization of FF nanotubes fabricated using two 
published methods. A variety of microscopy and other techniques including 
AFM, SEM, FIB-SEM, XRPD and Raman spectroscopy were applied. The 
differences in morphology of the tubes formed by different methods are 
discussed. This chapter concludes with a tentative suggestion of the peptide 
nanotube assembly pathway. 
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The work presented in Chapter 3 explores the biological properties of FF 
nanotubes. The cytotoxicity of the tubes on a HeLa cell line is investigated 
using a MTT assay. The tubes are manufactured by the two previous methods 
as described in Chapter two from a range of concentrations. The cytotoxicity is 
investigated after incubation with HeLa cells. Furthermore, other factors that 
may influence the cytotoxicity, such as the presence of HFIP and serum in cell 
culture medium are also explored.  
The experiments presented in Chapter 4 exploit the potential of FF tube as a 
drug carrier for delivery applications. Based upon the results from previous 
chapters, the scope of the chapter focuses on the utilization of FF tube as 
potential drug carriers. The opening section of the chapter documents the 
synthesis of nanotube-drug complex using two model drugs with different 
solvents at different loading concentrations. Characterization of the complex is 
investigated with SEM. In vitro drug release is performed showing a notable 
sustained manner.  
Finally, a brief summary of all the work and its implications is presented in 
presented in the last chapter. 
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Chapter 2 Characterization of Diphenylalanine 
Nanotubes 
 
2.1 Introduction  
2.1.1 Molecular self-assembly 
There are numerous examples in nature where complex biological structures 
are formed from repeat small building blocks through spontaneous self-
recognition processes on a nanoscale [149, 150]. Such processes, termed 
Ômolecular self-assemblyÕ, play a vital role in many biological systems [151]. 
Self-assembly facilitates the achievement of various biological functions but 
can also be part of a pathogenic process. Examples of this dichotomy are the 
folding of polypeptide chains into useful functional proteins and the formation 
of amyloid fibrils that are associated with a number of diseases such as 
diabetes and AlzheimerÕs [2, 152].  Self-assembly is also a principle theme in 
nanotechnology, where molecular self-recognition facilitated by a combination 
of different non-covalent interactions between simple building blocks allows 
the fabrication of functional 2- and 3-dimensional structures (Figure 2-1) [153-
156]. Such a so called Ôbottom-upÕ strategy, compared with the conventional 
Ôtop-downÕ methods, offers several advantages including ease of production 
and precise control of the final assembled structure by optimizing the starting 
building blocks. 
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Figure 2- 1 Schematic comparison between top-down and bottom-up approaches: 
bottom-up approaches describe the spontaneous formation of an ordered structure 
from individual disordered entities under thermodynamic equilibrium condition [156].
  
 
2.1.2 Diphenylalanine self-assembly 
Biological-based building blocks in self-assembly processes are favoured by 
researchers due to their potential biocompatibility and their ability for specific 
molecular recognition over non-biological systems [157-160]. Since the 
discovery of the role of FF in the formation of amyloid fibrils, there has been 
rapid progress in the investigation of assembled FF dipeptide [87, 161-164]. 
Methods of forming FF nanotubes in vitro have been developed. There are 
essentially two recognized approaches. It has been demonstrated by GazitÕs 
group that nanotube suspensions of FF can be rapidly obtained by dissolving 
FF peptide in an organic solvent, 1,1,1,3,3,3- hexafluoropropan-2-ol (HFIP), 
followed by dilution with water [76]. Another group led by Song have reported 
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an alternative method for preparing FF nanotubes omitting HFIP; FF peptide 
was heated at 65 ¡C in water for thirty minutes and the solution was then 
cooled to room temperature [89]. 
Over the past decade, applications of FF nanotubes have been widely spread 
over the field of nanotechnology. Studies have shown their utility as novel 
materials in nanoelectronics; for example, to act as scaffolds for nanowire [76],   
nanocomposite [89, 100, 101], and nanocable production [115], and as 
electrochemical biosensor platforms [131]. The applications of FF tubes in 
biological and pharmaceutical areas have been broadened by chemical 
modification of the FF peptide to form specific functionalized nanomaterials. 
For instance, by attaching the amino-terminal of FF with a 
fluorenylmethyloxycarbonyl (Fmoc) group, the derivatives have been shown to 
be capable of forming scaffolds for drug encapsulation and controlled release, 
and for supporting 2D and 3D cell culture proliferation [118, 124, 136, 141, 
145]. 
 
2.1.3 Objectives of this chapter 
The experiments within this chapter focus on the investigation of the physical 
properties of the FF nanotubes prepared by two different methods as previously 
described. The nanotube preparations were carried at the same peptide 
concentrations to investigate potential differences in morphology of the tubes 
formed. Knowledge of how FF nanotube self-assemble and the mechanism of 
fibril growth is important to understand their potential use; modification of the 
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tube size and other physical properties such as rigidity offer chances to broaden 
the scope of applications. For example the size of the tube is crucial when 
evaluating its potential as a drug carrier. A valid and reproducible method to 
produce homogenously sized tubes would be advantageous. 
 
2.2 Experimental  
2.2.1 Materials 
FF peptide and 1,1,1,3,3,3- hexafluoro-2-propanol (HFIP) were purchased 
from Sigma-Aldrich, UK.  
 
2.2.2 Method 
2.2.2.1 Nanotubes prepared in HFIP/water mixture 
Fresh stock solutions were prepared by dissolving the lyophilized peptide in 
HFIP at a concentration of 100 mg/mL. The peptide stock solution was 
subsequently diluted in double distilled water (ddH2O, pH 6.5, resistivity 18.2 
MΩcm) to a final concentration of 1 mg/mL and vortex mixed for 30 seconds. 
 
2.2.2.2 Nanotubes prepared in water alone 
Lyophilized FF peptide was dissolved in ddH2O (1mg/mL) at 65 ¡C. After a 
30 minute equilibration at 65 ¡C, solutions were allowed to cool to room 
temperature.  
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2.2.2.3 Sample characterization 
2.2.2.3.1 Atomic force microscopy imaging 
Aliquots (20 µl) of freshly prepared FF nanotube suspensions (as prepared by 
the methods stated above) were placed onto freshly cleaved mica substrates 
(Agar Scientific Ltd., Stansted, UK), and gently dried in a stream of nitrogen 
gas. Topographic and phase images of the sample were generated using a 
D3000 AFM (Bruker Nano/Bruker AXS, Santa Barbara, CA) with a J-type 
scanner. All imaging was performed in air in tapping mode using silicon TESP 
cantilevers (Veeco Metrology Group) with a nominal spring constant of 42 
N/m. The scan rates employed ranged from 1.0 - 2.0 Hz. Data was analyzed 
using Scanning Probe Image Processor (Image Metrology A/S, Denmark). 
Corresponding topography and cross-sectional analysis data are presented 
alongside images where appropriate. 
 
2.2.2.3.2 Scanning electron microscopy imaging 
Nanotube samples were dried on mica substrates following the same procedure 
as in the AFM sample preparation. The mica substrates were then mounted 
onto 12 mm aluminium sample stubs (Agar Scientific Ltd.) using carbon tabs 
(12mm diameter, Agar Scientific Ltd.) The samples were deposited with a thin 
layer of gold by low-vacuum sputter coating to facilitate imaging (argon gas 
with an ion current of 30 mA). SEM images were recorded using a JSM JEOL 
6060 SEM (JEOL, Tokyo, Japan) operating at 10 kV. The size of the tubes was 
measured using SM-35080 SMILE VIEW software. 
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2.2.2.3.3 Focused ion beam-scanning electron microscopy imaging 
Aliquots (20 µl) of freshly prepared FF nanotube suspensions were placed onto 
12 mm aluminium sample stubs (Agar Scientific Ltd.) and then allowed to dry 
at room temperature. The stub was then coated with carbon using a turbo 
carbon coater (Agar Scientific Ltd.) The images were collected at low 
electrical voltage to minimize the over charge of the sample. The milling 
process was undertaken by an ion beam current of 0.3 Ð 0.5 nA at a voltage of 
30 kV.  
 
2.2.2.4 X-ray powder diffraction 
XRPD measurements were recorded on a Bruker D8 (Bruker, Coventry, UK). 
Powders were loaded into glass capillaries (0.7 mm, Capillary Tube Supplies 
Ltd.). Data were collected in step scan mode between 2.0¡ and 90¡ (2θ) with a 
step size of 1¡ and a counting time of 10 s/step. The working conditions were 
10 kV and 30 mA. All peak positions were used for the determination of micro 
structural parameters.  
 
2.2.2.5 Raman spectroscopy 
Aliquots (20 µl) of freshly prepared FF nanotube suspensions were placed onto 
freshly cleaved mica substrates (Agar Scientific Ltd.), and gently dried in a 
stream of nitrogen gas. Spectra were recorded on a home-constructed Raman 
micro-spectrometer consisting of major components such as laser (785 nm, 
Photonica), microscope (Olympus), Spectrometer and CCD (Andor). Other 
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optics components included are microscope stage, lenses, plasma and Rayleigh 
filters (Prior Systems, Thorlabs, Newport and Semrock, respectively). The 
instrument was operated using a program developed in-house in Labview 
(National Instruments) which controlled the microscope stage, the spectrometer 
and the CCD camera. The beam path was 800 mm. 
 
2.3 Results 
2.3.1 Characterization 
2.3.1.1 AFM imaging 
Samples of the nanotubes formed by FF peptide were imaged by AFM using 
tapping mode imaging in air. The images shown in Figure 2-2 and Figure 2-3 
are representative AFM images of the dried FF nanotube samples formed in 
HFIP/water mixture and water alone, respectively. The range of diameters of 
the nanotubes observed is in agreement with previous work (from few 
nanometers to 2µm) [76, 78, 79, 92, 93]. AFM characterization of FF 
nanotubes was repeated on several tens of samples and the data showed good 
reproducibility.  
The AFM images presented in Figure 2-2 were taken from dried FF nanotube 
sample prepared by HFIP/water mixture. Figure 2-2a is a topography image of 
a selected nanotube displaying long, discrete and unbranched morphology with 
a slight bend along the tube. A 3D representation of the nanotube is presented 
in Figure 2.2b demonstrating the tubular nature of the structure. The selected 
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nanotube shows parameters in terms of height and half-height widths 
consistent with published values (Figure 2.2c) [80, 84, 93, 121].  
The AFM images shown in Figure 2-3 represent a selection of tubes formed in 
water alone. The 3D representation is presented in Figure 2-3b presenting long, 
straight, unbranched and tubular nature of the tubes. A profile of the nanotube 
cross-section (location is highlighted by the line in Figure 2-3a) is presented in 
Figure 2-3c showing data in agreement with published AFM measurement of 
FF tubes [80, 84, 93, 121]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- 2 AFM images of a FF nanotube formed in HFIP/water mixture. Figure 2-
2a is a topography image of the FF nanotube dried onto freshly cleaved mica 
substrate and imaged by tapping mode AFM in air. Figure 2-2b is a 3D 
representation and Figure 2-2c is a cross-sectional profile of the nanotube (location is 
highlighted by the line in Figure 2-2a). 
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Figure 2- 3 AFM images of FF nanotubes formed in water alone. Figure 2-3a is a 
topography image of the FF nanotubes dried onto freshly cleaved mica substrate and 
imaged by tapping mode AFM in air. Figure 2-3b is a 3D representation and Figure 
2-3c is a cross-sectional profile of the nanotube on the left (location is highlighted by 
the line in Figure 2-3a). 
 
2.3.1.2 SEM imaging 
Dried samples of FF nanotubes prepared by both methods were imaged by 
SEM under vacuum with the same experimental parameters (electrical voltage 
= 10kV, working distance from the lens to the sample = 30mm, and spot size = 
40mm).  
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2.3.1.2.1 SEM imaging of FF nanotubes formed in HFIP/water mixture 
Figure 2-4 presents a low resolution SEM image of a nanotube sample 
prepared in HFIP/water mixture. The nanotubes are closely associated with 
each other with lengths up to hundreds of microns; different areas of the 
sample are shown at higher resolution from Figures 2-5 to 2-8. Compared with 
published SEM studies on FF nanotubes that display long, straight and 
unbranched morphology, the results presented here show some interesting 
differences, which will be addressed below [79]. A size distribution of FF 
nanotubes was made based on a large number of samples (n>1000) and is 
presented in section 2.3.1.4. 
The SEM image presented in Figure 2-4 is a typical overview of the dried FF 
nanotube samples. The images in Figure 2-5 are selections of the nanotube 
samples viewed at a higher resolution (magnification ranges from x1700 to 
x6000). The bundles of nanotubes presented in Figure 2-5a display Ôcrystal-
likeÕ features: there is a repeating pattern of the tubes originating from a 
common nucleating centre and projecting outwards. The nucleation points are 
shown at higher resolution in Figure 2-5b and Figure 2-5c (as annotated by the 
arrows). 
 
 
 
Figure 2- 4 SEM micrograph of FF nanotubes prepared in a HFIP/water mixture 
dried onto freshly cleaved mica coated with gold and imaged by SEM in vacuum.  
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Figure 2- 5 SEM micrographs of FF nanotubes displaying nucleation points. Figure 
2-5a is a SEM image of nanotubes prepared in HFIP/water mixture dried onto freshly 
cleaved mica coated with gold and imaged by SEM in vacuum. The origins of tubes 
are shown by arrow in Figure 2-5b and Figure 2-5c at a higher resolution 
(magnification x6000). 
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The SEM images presented in Figure 2-6 are different areas of the dried 
nanotube samples. The diameters of the tubes are up to 2 µm and lengths are 
hundreds of microns, which are consistent with previous studies [79]. A 
selection of the straight portions and curved portion of the tubes from Figure 2-
6a (as highlighted by the black rectangle and the white rectangle, respectively) 
are presented at a higher magnification (x5500 and x2700, respectively) in 
Figure 2-6b and Figure 2-6c.  
 
 
 
 
 
 
 
Figure 2- 6 SEM micrographs of FF nanotubes. Figure 2-6a is a SEM image of 
nanotubes prepared in HFIP/water mixture. A high magnification of the straight 
portion of the nanotubes (as highlighted by the black rectangle in a) is shown in 
Figure 2-6b, and that of the curved portion of the nanotubes (as highlighted by the 
white rectangle in a) is shown in Figure 2-6c. 
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The ends of the tubes originating from common nucleating centres are 
displayed in SEM images shown in Figure 2-7. Unlike common rigid and 
straight tubular ends, the morphologies of the tube ending prepared in 
HFIP/water mixture show variation: some exhibit a certain degree of flexibility, 
presenting a Ôfeather-likeÕ morphology (Figure 2-7a) and some have merged 
with the substrate surface (Figure 2-7b). 
 
 
 
 
 
 
 
 
 
Figure 2- 7 SEM micrographs of FF nanotubes with ends with various features. Tubes 
were prepared in a HFIP/water mixture dried onto freshly cleaved mica coated with 
gold and imaged by SEM in vacuum. Figure 2-7a is a selection of the flexible ends of 
the tubes and Figure 2-7b is a selection of the tube ends merged with substrate surface  
(as indicated by the arrows). 
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Furthermore, a number of small structures and round objects were also seen in 
the samples (Figure 2-8). As shown in Figure 2-8a, a large number of small 
structures with lengths in the range of less than 5 µm to 20 µm are presented 
alongside the tube bundles. A high-resolution image (magnification x4000) is 
shown in Figure 2-8b. These needle-shaped structures are relatively large at 
one end and pointed on the other end, and can branch out (Figure 2-8c, 
highlighted by the arrows). There are also a number small round objects with 
diameters less than 10 µm seen in the nanotube samples, an example of which 
is shown in Figure 2-8d.  
 
 
 
 
 
 
 
 
 
 
Figure 2- 8 SEM micrographs of short FF nanotubes. Figure 2-8a is a SEM image of 
nanotubes prepared in HFIP/water mixture dried onto freshly cleaved mica coated 
with gold and imaged by SEM in vacuum. A high resolution of the short, needle-like 
objects presented in Figure 2-8a (as highlighted by the rectangle) is shown in Figure 
2-8b with a magnification x4000. The branching-out features were observed in Figure 
2-8c (as indicated the arrows). Small round objects were also observed (Figure 2-8d). 
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2.3.1.2.2 SEM imaging of FF nanotubes formed in water alone 
SEM images of the nanotube samples prepared by the aqueous method are 
presented in Figure 2-9 and Figure 2-10. The tubes have a similar morphology 
to that observed previously [79, 89]. Long, unbranched, and discrete tubular 
nanostructures are seen. A size distribution of FF nanotubes was made based 
on a large number of samples and is presented in section 2.3.1.4. 
Figure 2-9 is a typical SEM image of the FF nanotubes prepared in water alone. 
In contrast to the images presented in Figures 2-4 to 2-8 (nanotubes formed in 
HFIP/water mixture), the image shown in Figure 2-9a presents well-formed 
nanotubes that are loosely distributed on the substrate. The distribution appears 
random, with the nanotubes not associated with each other, and no ÔoriginsÕ of 
growth. A higher-resolution image of the tubes (as highlighted by the rectangle 
in Figure 2-9a) is presented in Figure 2-9b, displays a range of tubular 
diameters up to a few microns and lengths up to hundreds of microns. These 
values are in agreement with previous published data by SongÕs group in which 
they stated the FF tubes prepared by their procedure had a diameter that ranged 
from 100 nm to 2 µm and an exceeded length of 100 µm [89]. 
In addition, the ends of some of the FF tubes were observed to be hollow 
(Figure 2-10). Figure 2-10a is an SEM image of the tubes, where a tube with a 
hollow end is presented (highlighted by the rectangle). Under higher 
magnification, as presented in Figure 2-10b, the tube has a diameter around 20 
µm and appear to be made up of bundles of tubes of smaller dimensions (~ 1 
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µm); the small tubes stack together and arrange themselves into a bigger tube 
with a hollow centre. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- 9 SEM micrographs of FF nanotubes. Figure 2-9a is a SEM image of 
nanotubes prepared in water alone and dried onto freshly cleaved mica coated with 
gold and imaged by SEM in vacuum. A higher-magnification image of the rectangle 
highlighted in Figure 2-9a is shown in Figure 2-9b (magnification x450).  
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Figure 2- 10 SEM micrographs of FF nanotubes. Figure 2-10a is a SEM image of 
nanotubes prepared in water alone and dried onto freshly cleaved mica coated with 
gold and imaged by SEM in vacuum. A tube with a hollow end is annotated by the 
rectangle, and a higher-magnification image of which is presented in Figure 2-10b 
(magnification x2700). 
 
2.3.1.3 Focused Ion Beam-SEM 
A focused ion beam-SEM (FIB-SEM) study was performed on dried nanotube 
samples prepared using the water alone method. The aim of the experiment 
was to view the interior structure of the nanotubes bundles (as in Figure 2-10b) 
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by cross-sectional cutting the tube with a focused beam of ions at a precise 
position. 
The FIB-SEM images presented in Figure 2-11 are of the nanotubes imaged by 
the primary beam of electrons at low current (5 kV). This allows SEM imaging 
of the sample as in standard SEM. Figure 2-11a is an overview of the FF 
nanotube samples dried on aluminium stub coated with carbon film. Figure 2-
11b shows a bundle of nanotubes found with a diameter of around 13 µm. The 
position where the ion beam impacts the tube surface is indicated by the 
rectangle. Figure 2-11c is an end view of the bundle where a number of tubes 
with smaller dimensions stacking together in the direction of the bundle axis 
can be seen. 
After localizing the position (as indicated by the rectangle in Figure 2-11b), a 
high voltage (30 kV) focused ion beam was applied and the milling process 
was induced. The ion beam impact at the tube surface generated secondary 
electrons and secondary ions which can be collected to generate a series of 
images of the milling process. The images presented in Figure 2-12 are a series 
taken at a time interval of seconds. As shown in Figure 2-12a to Figure 2-12d, 
the beam was scanned across the bundle surface which gradually cut a cross-
section area. A higher-resolution view of the cross-sectional area of the tube 
bundle is presented in Figure 2-12e. The tube displays a hollow core with a 
diameter of about 1 µm. There are also smaller holes that might be the core of 
the smaller tubes stacked together, the axes of which run parallel to the 
direction of the bundle axis. 
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Figure 2- 11 FIB-SEM micrographs of FF nanotubes. Figure 2-11a is a SEM image of 
nanotubes prepared in water alone and dried onto aluminium stub coated with carbon 
film. The tube bundle with rectangle annotated is where the ion beam was applied 
(Figure 2-11b). Figure 2-11c is the end view of the tube bundle.  
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Figure 2- 12 FIB-SEM micrographs of FF nanotubes. Images presented in Figure 2-
12a to Figure 2-12d are images of the milling process captured at second time 
intervals. A higher-resolution of the cut cross sectional area is presented in Figure 2-
12e. The hollow centre can be seen (as indicated by the arrow) with small holes 
running parallel to the direction of the tubular axis.  
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2.3.1.4 Size measurement of FF nanotubes prepared by both methods 
Size distributions of the nanotubes were determined for both methods of 
preparation based on the SEM data; length and width measurements were taken 
using SM-35080 SMILE VIEW software. 
A representation of the length measurement of the nanotube samples prepared 
by both methods is displayed in Figure 2-13. Figure 2-13a is an SEM image of 
nanotube samples prepared in HFIP/water mixture. As seen previously these 
tubes are nucleated from a common origin and projecting outwards. The 
lengths of the tubes was determined by drawing a line from one end of the tube 
to the other end using the SMILE VIEW software (as indicated by the double 
arrowed line), and the length is automatically recorded (length = 92 µm of the 
tube presented in Figure 2-13a). Figure 2-13b is an SEM image of a nanotube 
sample prepared in water alone. Similar to previous SEM results, this method 
produced long, straight, and unbranched nanotubes. The length of the selected 
tube is 157 µm. Based on a large number of measurements (n > 1000) of tubes 
prepared by both methods, a length distribution is plotted in Figure 2-13c. The 
ÔHFIP/water methodÕ produces nanotubes with relatively shorter length, 
ranging from the nanoscale to > 300µm, with 54 % (n = 1108) in the range up 
to 50 µm. The Ôwater-alone methodÕ, on the other hand, gives a wider 
distribution; the tube length is up > 1400 µm, with 24% (n = 650) in the range 
up to 50 µm. 
A representation of the width measurement of the nanotube samples prepared 
by both methods is presented in Figure 2-14. The width measurement of a tube 
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was undertaken by drawing a line from one side of the tube to the other using 
the software (as indicated by the line), with the width being automatically 
recorded. As shown in Figure 2-14a and Figure 2-14b, the selected tubes 
formed in HFIP/water mixture and the ones in water alone have diameters of 
680 nm, 1200 nm and 1600 nm, respectively. A width distribution is presented 
in Figure 2-14c. The width distribution of the tubes formed in HFIP/water 
mixture ranged up to 2240 nm, with 40% between 200 nm and 300 nm. The 
tubes prepared in water alone, in contrast, were wider with widths up to 3620 
nm, with 9% in the range of 600-700 nm. This result is consistent with 
previous studies which have also confirmed the water-alone procedure 
produced FF tube with wider dimensions than the ones produced by 
HFIP/water mixture [76, 89]. This is in good correlation with the AFM study; 
the half-height widths of the tubes prepared in the HFIP/water mixture and the 
water alone are 348 nm (± 9 nm) and 606 nm (± 13 nm), respectively (data 
presented as mean ± SEM, n = 27), which is in good agreement with the SEM 
data presented earlier. 
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Figure 2- 13 Length measurement of FF nanotubes prepared by two methods. Figure 
2-13a and Figure 2-13b are example SEM images of the tube samples formed in 
HFIP/water mixture and water alone, respectively. The double arrowed lines indicate 
the length measurement of the tubes. A distribution plots of FF nanotube (n > 1000) 
prepared in HFIP/water mixture (shown in red), and in water alone (shown in blue) is 
presented in Figure 2-13c. 
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Figure 2- 14 Width measurement of FF nanotubes prepared by two methods. Figure 
2-14a and Figure 2-14b are example SEM images of the tube samples formed in 
HFIP/water mixture and water alone, respectively. The lines indicate the width 
measurement of the tubes. A distribution plot of FF nanotube (n > 1000) prepared in 
HFIP/water mixture (shown in red), and in water alone (shown in blue) is presented 
in Figure 2-14c. 
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2.3.2 Raman Spectroscopy 
Raman spectroscopy was performed on dried nanotube samples prepared by 
the two approaches. The advantage of the Raman spectroscopy in 
characterization over the microscopy techniques such as AFM or SEM is that 
the data has chemical and physical state sensitivity [85]. The chemical 
structure of FF is shown in Figure 2-15. The fingerprint region of most organic 
molecules is between wave numbers 500 Ð 2000 cm-1. The Raman spectra of 
the tubes formed by two methods are presented in Figure 2-16, a subtraction of 
the spectra is shown at the bottom. The Raman bands which can be attributed 
to the aromatic rings in the FF are at 1009 cm-1, 1038 cm-1, 1590 cm-1, and 
1610 cm-1 [85, 165].  Other characteristic bands found are at 1433 cm-1 and 
1688 cm-1, which were assigned to C-H bending within the alkyl groups and 
C=O stretching, respectively [85, 165].  The small peaks detected between 
1100 cm-1 to 1300 cm-1 were attributed to the acyclic C-C stretching [85, 165].  
The Raman band of the primary aliphatic amide bond C-N (1020 - 1090 cm-1), 
however was not observed. A summary of the chemical groups of FF and the 
corresponding Raman shift values is listed in Table 2.1. The similar 
characteristic bands are observed from both Raman spectra of the tubes made 
by both methods and there is no significant difference between the two spectra. 
 
 
 
                                     Figure 2- 15 Molecular structure of FF. 
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Figure 2- 16 Raman spectra of dried nanotube samples. Top blue pattern represents 
spectrum of the nanotube prepared in HFIP/water mixture (as shown in Figure 2-2a), 
middle red pattern represents spectrum of the nanotube prepared in water alone (as 
shown in Figure 2-3a, the one on the right), a subtraction of the spectra is shown in 
black at the bottom. 
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Table 2. 1 Chemical groups of FF and the corresponding Raman band values with 
relative intensities [165]. 
 
2.3.3 X-ray powder diffraction 
In addition to Raman spectroscopy, X-ray powder diffraction was performed 
on dried nanotube samples prepared in both solvents so as to characterize, if 
there is any difference, in the crystal form of the nanotubes prepared by 
different methods.  
A spectra summarizing the XRD patterns of the tubes from the two methods is 
displayed in Figure 2-17 and the subtraction of the two spectra is shown at the 
Chemical groups 
Raman spectra 
Region/cm
-1
 
Intensity 
C-N stretching (primary 
aliphatic amine) 
1020-1090 Weak 
C-C aromatic stretching 
1000 
1450-1500 
1580-1600 
Strong 
Medium 
Strong 
C-C acyclic, aliphatic 
stretching 
600-1300 Medium 
CH2 bending 1400-1470 Medium 
C=O stretching 1680-1820 Strong 
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bottom. All of the peaks are in good alignment. The subtraction of the spectra 
indicates that there is little/no difference observed between the two patterns. 
To validate the results obtained in this experiment, a control study was 
performed on the prepared nanotube samples of the same batch (formed in 
HFIP/water mixture), and comparing the obtained experimental diffraction 
pattern with a simulated diffraction pattern from the database (CCDC 163340 
file). As shown in Figure 2-18, the observed experimental peaks of the 
nanotube are in good agreement with a simulated powder diffraction pattern of 
the previously reported spectrum of the single crystal. This result is consistent 
with previous published XRPD studies on FF nanotubes [97].  
 
 
 
 
 
 
 
 
Figure 2- 17 XPRD patterns of FF nanotubes prepared (a) in water/HFIP mixture and 
(b) in water alone, and a subtraction of the two patterns reveals that the patterns are 
essentially identical. 
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Figure 2- 18 XRPD pattern of nanotubes prepared in HFIP/water mixture. Dot marks 
represent the observed intensities, and the solid line defines calculated data of the 
single-crystal structure. Tick marks in the middle indicate the reflection positions and 
a difference between observed and calculated intensities is shown at the bottom. 
 
2.4 Discussion 
The SEM data presented in Figures 2-4 to 2-10 indicate that there are subtle 
differences in morphology and physical properties of the nanotubes prepared 
by the two methods. In general, the morphology of nanotubes prepared in the 
HFIP/water mixture presented in Figure 2-4 to 2-8 appear to have four defining 
features: the roots of these nanotubes are shown to be nucleated from a site of 
origin (Figure 2-5a and b shown by arrows) and projecting outwards (Figure 2-
5c); along the tube length some tubes are long and straight (Figure 2-6a and b), 
whereas some other tubes show bending features stacking together (Figure 2-
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6c); the ends of these tubes are quite flexible (Figure 2-7a) and some are open 
ended (Figure 2-7b); moreover, there are some short, needle-shaped structures 
that might be early stage nanotubes (Figure 2-8a and b), Ôbranching outÕ 
features of these short objects are seen (Figure 2-8c shown by the arrows), and 
small structures that might represent a precursor structure (Figure 2-8d). In 
contrast, the tubes prepared in water alone were discrete with no apparent 
nucleation points or tube-tube association (Figure 2-9). They display long, 
straight, and unbranched morphology similar to previous work on FF 
nanotubes [76, 89]. 
This difference in tube dimension was evaluated by size distribution 
undertaken from SEM data (Figure 2-13 and 2-14). These results show good 
correlation to AFM analysis. These studies have confirmed the physical 
property difference of the tubes made by different methods. 
Furthermore, large bundles of nanotubes were observed in tubes from the water 
alone method of preparation (Figure 2-10). As can be seen from the high-
resolution SEM image presented in Figure 2-10b, these aggregates are made up 
of smaller tubes stacking together to give the final tubular structure. This was 
confirmed by the interior cross-sectional morphology view from the FIB-SEM 
study (Figures 2-11 and 2-12). The large tube was indeed hollow from its 
cross-sectional view, with small holes that appear to be the cores of the smaller 
tubes running parallel to the direction of the tube axis. This finding is in 
agreement with previous studies which suggested that there are parallel 
channels running in the direction of the tube axis of some large FF nanotubes 
[89, 98]. 
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In order to understand the observed differences in morphology of the FF tubes 
prepared by the two methods, knowledge of the formation mechanism is 
required. To date, there has been no clear elucidation of the mechanism 
underlying FF nanotube self-assembly, however, similar work has been 
undertaken on β-amyloid (Aβ) [95, 166-168]. In vitro studies have suggested 
that Aβ fibrillogenesis occurs in two distinct stages, nucleation and elongation 
of fibrils (Figure 2-19). The nucleation stage involves a series of energetically 
unfavoured steps where soluble protein monomers form stable nuclei; then 
elongation proceeds in which the nucleus rapidly grows to form larger fibrils 
[166]. The characteristic features of such a nucleation-dependent formation 
pathway are that no nucleation occurs at a protein concentration below a 
critical concentration; elongation of the fibrils stops when soluble protein 
monomers are exhausted. The length of the fibrils is inversely proportional to 
the total number of nuclei and that the elongation process follows first order 
kinetics, i.e. the monomers bind to the tip of the fibril at a rate that is 
proportional to the monomer concentration [166] This rate constant varies with 
conditions such as pH, temperature, and ionic strength [166]. Although there is 
no direct evidence proving the mechanism of FF nanotube formation is similar 
to that of Aβ fibrillogenesis, nevertheless FF which is the core recognition 
motif of Aβ and undoubtedly plays a vital role in Aβ fibril formation, 
furthermore the type of interactions responsible for and stabilize Aβ formation 
and FF nanotube formation are similar. There could be similarities in the 
underlying mechanism of formation between the two models.   
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Figure 2- 19 Schematic representation of Aβ fibrillogenesis. * Means critical 
monomer concentration. 
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If a similar mechanism takes place in FF nanotube formation it is proposed that 
the difference in the FF tubes revolves primarily around the effect of HFIP 
(HFIP/water method) and heat (water method) on environmental conditions 
and solubility of the FF peptide which impacts on nucleation and growth 
kinetics. Firstly, it should be noted that the prepared peptide concentration is 
the same for both methods, although the solubility of the peptide in HFIP/water 
may be different than that in water at 65¡C. As both samples display tubes, the 
achieved concentration of solubilised FF must be above the critical level 
required to achieve nucleation in the different solvents, or to continue 
elongation on preformed small tubes. However, the absolute value of this 
critical concentration is likely to be different in HFIP/water and water alone. 
The dilution with water of the HFIP may lead to ordering of the peptide at the 
HFIP-water interface with hydrophobic moieties oriented away from the 
aqueous phase providing an energetically favourable environment for the 
nucleation stage. This proposal is consistent with previous work in which it 
was suggested that the formation of the tubes (prepared by HFIP/water method) 
may be at the surface of the peptide solution [162]. The water-only method 
omits HFIP and involves heat. Since FF peptide is sparingly soluble in water at 
room temperature, heat is required to increase the solubility of the monomers 
to trigger nucleation. Although it should be noted that at 65¡C insoluble 
particulates of FF could still be observed in the solution, it has nevertheless 
exceeded the critical concentration of FF to facilitate nucleation. Hence 
nucleation may be proceeding via a homogeneous nucleation route unaided by 
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a liquid-liquid interface or the insoluble aggregates may be playing a role in 
initiating nucleation.  
The lower concentration of peptide in the water alone method (as indicated by 
the insoluble material) may favour the growth of a smaller number of tubes at a 
slower rate, but to an eventual greater length due to reduced crowding of the 
tubes as suggested by the SEM imaging of the HFIP/water samples. The 
increased time for growth may also allow a greater order in the molecular 
structure of the tubes and hence greater rigidity. However, it should be noted 
that the Raman Spectroscopy and XRPD data did not differentiate the tubes 
based upon internal molecular organization. Hence the assembled structure at 
the molecular scale level is identical. 
The Raman Spectroscopy and XRPD results for FF nanotubes prepared by both 
methods are in good agreement with previous theoretical data and work where 
the unit cell was shown to be comprised of six FF molecules per turn that 
orient with the aromatic rings arranged outwards [96, 98].  π-π Interactions 
between adjacent aromatic rings and hydrogen bonding between peptide back 
bones were proposed to be the main forces that stabilize the tubular structure. 
In addition, the C=O bonds are perpendicular to the C-N bond and are aligned 
along the nanotube axis [85]. 
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2.5 Conclusions 
The studies in this chapter presented a comparative analysis of the structural 
properties of FF nanotubes prepared by the two established methods. FF 
peptide undergoes rapid self-assembly in vitro in both methods and the 
nanotubes produced present subtle differences in morphology. In general, FF 
nanotubes prepared in HFIP/water mixture are smaller in dimension and 
display bend features. Some nucleation centres were seen in these samples, 
with nanotubes projecting outwards from a core. The second method that 
involves only warm water as a solvent produced longer, discrete, and straight 
nanotubes with larger dimension. Raman spectroscopy and XRPD data have 
shown these nanotubes are indistinguishable by these techniques in terms of 
their molecular organization. The precise mechanism of growth for each type 
of nanotube is yet to be determined although comparison can be drawn with 
models related to the growth of amyloid fibrils. The role of the solvent HFIP 
appears critical in promoting significant nucleation and the consequent 
differences between the two types of tubes.  
 
 
Chapter 3 Diphenylalanine nanotube-cell interactions 
  69 
Chapter 3 Studies on Diphenylalanine Nanotube-Cell 
Interactions 
 
3.1 Introduction 
To date, applications of diphenylalanine (FF) nanotubes have focused on the 
area of nanoelectronics [76, 80, 93, 100, 101]. The physico-chemical properties 
of the tubes such as surface, thermo-mechanical and optical properties have 
been intensively studied [79, 85, 106], leaving the potential of FF nanotubes 
for pharmaceutical applications relatively unexplored. On the other hand, the 
cytotoxicity and biological potentials of carbon nanotubes, which were 
discovered approximately 30 years ahead of FF nanotubes have been assessed 
intensively [169-172]. Various cell lines and in vivo tests have been used to 
investigate the biocompatibility of carbon nanotubes. In vitro tests involve a 
number of cultured human cell lines, for example, cultured human blood cells, 
A549 lung cells, HeLa cells, and dermal fibroblasts [173-180]. In vivo tests 
include animal testing, for instance, subcutaneous tissue of rats [181-183]. Cell 
viabilities have been assessed using various indicator dyes, for example, 
Coomassie Blue, Alamar Blue, Neutral Red, MTT and WST-1, which evaluate 
the total protein content of cells, metabolic, lysosomal and mitochondrial 
activity respectively [174, 184-190]. Different factors that affect the 
cytotoxicity properties of carbon nanotubes have also been investigated, such 
as the type of carbon nanotubes (multi-walled vs. single-walled), the length, 
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specific surface area, and functionalization of carbon nanotubes, the choice of 
dye and possible interaction with nanotubes, and the interaction between serum 
in test medium and nanotubes [184, 188, 191-202]. A number of drug 
compounds have been successfully linked to the surface and to the end of 
carbon nanotubes [203, 204], examples include anticancer drugs such as 
methotrexate [205] and antitumor drugs such as 10-hydroxycamptothecin [206]. 
The anticancer activity/antitumor activity of the incorporated drugs had been 
proven to be enhanced from both in vitro and in vivo studies. For example, 
methotrexate when conjugated with multi-walled carbon nanotubes was shown 
to have an enhanced anticancer activity on a human breast cancer cell line 
[205]. Furthermore, in vivo single photon emission computed tomography 
imaging showed that 10-hydroxycamptothecin combined multiwalled carbon 
nanotubes had relatively long blood circulation and high drug conjugation in 
the tumour site [206]. Taken together, the research on carbon nanotube - drug 
complexes has indicated possible advantages of carbon nanotubes over 
conventional drug carriers (such as liposomes) due to their unique electrical 
properties, tubular shapes, and mechanical strength [207-211]. 
Compared with conventional drug carriers, FF nanotubes present several 
advantages: they self-assemble under mild conditions, so the manufacture is 
inherently scalable, simple and cost-effective; chemical modification and 
functionalization are easily achievable [78, 79, 162]. In contrast to carbon 
nanotubes, FF nanotubes are peptide based thus the biocompatibility problems 
of carbon nanotubes, such as debatable cytotoxicities raised from various 
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cytotoxicity assays with different cell lines [191], and poor excretion observed 
from in vivo studies [171], are less likely to occur with FF nanotubes.  
Despite the apparent advantages FF nanotubes can offer in drug delivery, there 
are limited publications on FF nanotube-based drug delivery systems. Recently, 
a study investigated the cytotoxicity of FF-based hydrogel formed by a FF 
analogue comprising an-α, β-dihydrophenylalanine residue (ΔPhe) containing 
dipeptide H-Phe-ΔPhe-OH.  The cytotoxicity was assessed on HeLa and L929 
cells after exposure to the hydrogels using a MTT 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay. FF-based hydrogels showed no 
influence on the cells in vitro; the cell metabolic activity was maintained over 
90% after 18 hours of incubation with the hydrogel [212]. 
The work presented here aims to provide more information regarding the 
biological properties of FF nanotubes by assessing the cytotoxicity of FF 
nanotubes on a HeLa cell line via a MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. The cytotoxic results were compared with 
that of the peptide alone. Furthermore, the effect of starting peptide 
concentration, the presence of serum in cell culture medium, and the presence 
of HFIP used in one of the preparation methods on the cytotoxicity of the 
nanotubes were also investigated. The stability of nanotubes in cell culture 
medium was assessed using SEM and nanotube-cell interactions were studied 
using total internal reflection microscopy (TIRM). Taken together, these 
studies provided knowledge of the biological properties of FF nanotubes.  
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3.2 Materials and Methods 
3.2.1 Materials 
HeLa cells were purchased from the European Animal Cell Culture Collection. 
All cell culture reagents such as DulbeccoÕs modified EagleÕs medium 
(DMEM), Phosphate buffered saline (PBS), sodium dodecyl sulfate (SDS), 
N,N-dimethylforamide (DMF), 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), and Mass spectroscopy materials 
including formic acid and acetonitrile were purchased from Sigma Aldrich.  
 
3.2.2 Methods 
3.2.2.1 Cell culture  
HeLa cells were cultivated on 75 cm2 flasks in DulbeccoÕs modified EagleÕs 
medium (DMEM) supplemented with 10 % foetal bovine serum (FBS), 2 mM 
L-glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin. Flasks were 
incubated at 37 ¡C and in an atmosphere of 5% CO2. Cells were trypsinized 
every 3 days. The medium was first aspirated out, and then cells were rinsed 
with 10 ml of PBS. Trypsin-EDTA (5 ml, 0.25%, composed of 2.5 g porcine, 
trypsin and 0.2 g EDTA, 4Na/L HBSS) was applied to dissociate cells from the 
flask. The flask was incubated for approximately 5 minutes until cells were 
detached from the flask and suspended in trypsin. Medium (10 ml) containing 
10 % of serum was added to the flask to stop the reaction of trypsin.  
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The cell suspension was transferred to a centrifuge tube and centrifuged for 5 
minutes at a speed of 13,000 rpm. The supernatant was pipetted out and cells 
were left at the bottom of the tube. Medium (10 ml) containing 10 % serum 
was applied into the tube and the cell pellet was re-suspended several times to 
ensure a good mixing. Cell suspension (1 ml) was then transferred into a new 
flask, along with 9 ml of pure medium containing 10 % serum.  
 
3.2.2.2 Cytotoxicity assay 
3.2.2.2.1 Determination of Optimal number of cells per well 
Cells were trypsinized as described above. After the cell suspension had been 
centrifuged, cells were diluted in 3 ml of medium containing 10 % serum. Cell 
suspension (100 µl) was placed in a microcentrifuge tube, followed by addition 
of 100 µl of trypan blue and thorough mixing. Trypan blue is a vital dye. The 
reactivity of trypan blue is based on the fact that the chromophore is negatively 
charged and does not interact with the cell unless the membrane is damaged. 
Therefore, living cells are excluded from staining.  
A hemocytometer was used for cell counting. A Pasteur pipette was used to 
transfer a small volume of the trypan blue-cell suspension to a chamber on the 
hemocytometer (This was done by carefully touching the edge of the cover-slip 
with the pipette tip and allowing the chamber to fill by capillary action). 
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All the living cells were counted (non-viable cells stain blue, viable cells will 
remain opaque) in the four squares of the chamber. Cell counting was repeated 
on the other chamber of the hemocytometer.  
The subsequent cell number per ml of cell suspension was determined using 
the following equation (Equation 3.1) and diluted to obtain 500,000 cells/ml or 
200,000 cells/ml. 
Cells / ml = no. of cells (per square) x dilution factor x 104      (3.1) 
Medium containing 2% serum (100 µl) was added to each well from column 3 
to 10 of a flat bottom 96 well plate (Corning, NY). Cell suspension (200 µl) 
was added to each well in column 2. Dilutions were made by transferring 100 
µl of cell suspension from a previous column to the next column using a multi-
channel pipette (Fisherbrand, UK). Thus a 1:2 dilution was achieved, with cell 
number per well starting from 50,000 and 20,000. Pure medium was added to 
column 11 as a control. 
Plates were incubated (37¡C, 5% CO2) for 24 hours before the cell culture 
medium was removed from each well. Fresh medium containing 10% serum 
(100 µl) and 50 µl of MTT (0.5mg/ml in PBS) added into each well. Cells were 
incubated at 37 ¼C and stirred on an orbital shaker (Memmert, Germany).  
Solution was removed after a 4-hour exposure, and rinsed with 100 µl of PBS. 
One hundred micro litre of SDS (10 %, in 50 % DDH2O and 50 % DMF) was 
added to each well, and plates were left in an oven on the orbital shaker 
(approximate 20-24 hours) until all formazan crystals had been dissolved. The 
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absorbance of each well was determined in a Spectra Max automatic multi-
plate reader (Dynex, USA) at 570 nm. The determination of optimal number of 
cells/well was done on three different occasions, with two plates (6 wells/plate) 
for each occasion. 
 
3.2.2.2.2 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay 
The cytotoxicity of different concentrations of FF nanotubes prepared by both 
methods in presence or absence of serum in the medium was evaluated on 
HeLa cells (passage number: from 25 to 41) using the colorimetric MTT assay. 
MTT assay measures the activity of reductase enzymes that reduce MTT dyes 
(yellow colour) to formazan dyes (purple colour). Such enzymes are only 
active in living cellsÕ mitochondria, therefore the conversion can be used to 
measure cellular metabolic activity [189]. 
Medium was removed after 24 hours. FF nanotubes were prepared according 
the method described in Section 2.221 and 2.222 of Chapter 2. FF nanotube 
suspensions were dried overnight at 65¡C in an oven, then re-hydrated with 
DMEM (4 ml) with or without serum at room temperature and stored at 4 ¡C. 
Free FF peptide solutions were made by dissolving FF powder in medium with 
or without serum, then left to dissolve at room temperature and stored at 4 ¡C. 
Cell suspension was prepared by diluting cells in medium containing 2 % 
serum to obtain 100,000 cells/ml. Cell suspension (100 µl per well) was plated 
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in a 96 well plate from column 2-11. Plates were incubated (37 ¡C, 5 % CO2) 
for 24 hours to allow the cells to attach to the wells. 
The medium was removed as described previously and cells were exposed to 
100 µl of different concentrations of FF nanotubes or free FF peptide in 
medium with or without serum (suspensions were pre-heated to 37 ¡C in a 
water bath). Nanotube suspensions (100 µl) with a starting FF concentration of 
1000 µg/ml were seeded to the first column of 96 well plate, subsequent 
dilution of the tube suspension by a factor of 2 were added to the next columns. 
Different controls were used. Firstly, the cell culture medium was used as a 
negative control representing 100 % metabolic activity. Secondly, 2% w/v of 
SDS in medium was used as a positive control representing 0% metabolic 
activity. Thirdly, HFIP (1 % in DDH2O, i.e. same concentration as used in the 
preparation of the nanotubes) after evaporation overnight at 65 ¡C and re-
suspension of the residue in cell culture medium was used to evaluate the 
cytotoxicity of the residue solvent in FF nanotubes prepared in HFIP/water 
mixture. Plates were incubated at 37 ¡C in the incubator.  
Nanotube suspensions were removed from each well after 20 hours of 
exposure. Medium (100 µl) containing 2% serum and 50 µl of MTT solution 
was added on to each well. Plates were incubated at 37 ¡C on the shaker for 4 
hours. Solution was then removed and each well was rinsed with 100 µl of 
PBS. SDS (100 µl, 10%) was added to each well, and plates were then stirred 
at 37 ¡C until all the formazan crystals had dissolved. Absorbance was read at 
a wavelength of 570 nm.  
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The percentage metabolic activity was calculated by subtracting the absorbance 
of the positive control (dead cells) then dividing each value by the negative 
control (100 % metabolic activity) x 100 %. Each cytotoxicity assay was 
performed on two cell passage numbers (2 plates, 6 wells per plate). 
 
3.2.2.3 Scanning electron microscopy (SEM) characterization of FF tubes 
in cell culture medium 
Pre-prepared FF nanotube suspensions (For methods of preparation, please 
refer to Section 2.221 and 2.222 of Chapter 2) were dried overnight at 65 ¡C in 
an oven. DMEM with 5 % serum was then added to the vial containing dried 
nanotubes. The DMEM-nanotube suspension was stored for 24 hours at 4 ¡C.  
Aliquots (20 µl) of the suspension (pre-heated to 37 ¡C in a water bath) were 
placed onto freshly cleaved mica substrates (Agar Scientific Ltd., Stansted, 
UK), and gently dried in a stream of nitrogen gas. The mica substrates were 
then mounted onto 12 mm aluminium sample stubs (Agar Scientific Ltd.) using 
carbon tabs (12 mm diameter, Agar Scientific Ltd.) The samples were then 
coated with a thin layer of gold to facilitate imaging (argon gas with an ion 
current of 30 mA). SEM images were recorded using a JSM JEOL 6060 SEM 
(JEOL, Tokyo, Japan) operating at 10 kV.  
 
3.2.2.4 Mass spectroscopy 
FF nanotubes were prepared in HFIP/water mixture using the standard protocol 
(please refer to Section 2.221), dried at 65¡C overnight and re-hydrated with 
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double distilled water (DDH2O) to the same concentration. The mass 
spectrometer used was a 2795 spectrometer with electrospray ionization 
(Waters, UK). 
Positive mode 
Sample suspension (10 µl) was transferred into a sample vial using a pipette. 
Formic acid (200 µl, 0.1 %, Sigma Aldrich) in DDH2O and 200 µl of 0.1 % 
formic acid in acetonitrile (Sigma Aldrich) were added to the suspension 
Negative mode  
Sample suspension (10 µl) was transferred into a sample vial using a pipette. 
DDH2O (200 µl) and 200 µl of acetonitrile were added to the suspension.  
 
3.2.2.5 Total internal reflection microscopy (TIRM) 
DMEM-nanotube suspension was prepared according to the method described 
earlier in Section 3.222 of this chapter. HeLa cells (100,000 cells/ml) in 1 ml of 
DMEM (containing 2 % serum) were seeded on a glass cover slip (Sigma and 
Aldrich) coated with polystyrene (Sigma and Aldrich) and placed inside of a 
cell culture disc for 24 hours. The glass cover slip was then transferred into the 
sample holder of the microscope with the addition of 1 ml of fresh DMEM 
(10% serum) and 100 µl of DMEM-nanotube suspension. 
All studies were performed using a custom-built widefield high-resolution 
inverted microscope. TIRM imaging of living cells was achieved with a light 
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emitting from a HeNe laser with the wavelength of 633 nm (LXHL-ML1D 
Luxeon Star, Lumileds, CA). The beam was expanded to fill the back aperture 
of the objective (Nikon, CFI  Apochromat  x60, NA1.49, oil immersion) for 
high spatial resolution. A rotating ground glass diffuser was placed at the 
conjugate plane of the back focal plane of the objective in order to achieve a 
spatial incoherence Koehler illumination.  The camera utilized to acquire 
images was a monochromatic CCD (Sony XCD-SX910) with 1280 (H) x 960 
(V) resolution. For video imaging, frames were streamed to a kinetic image 
disc on a PC and then saved to hard disc. Analysis of still images and video 
sequences was performed with ImageJ.  
 
3.2.2.6 Statistical analysis 
All results are expressed as the mean ± standard error of the mean (SEM).  
The GraphPad Prism (GraphPad Software, USA) for Windows was used for 
statistical evaluations. Differences between treatment and control groups were 
tested by standard T-test (one-tailed, two samples assuming equal variance); 
effect of peptide dilution was tested by one-way analysis of variance (one-way 
ANOVA), effect of serum combined with peptide dilution was tested by two-
way ANOVA without replication, followed by multi-comparisons between 
groups using Tukey-KramerÕs test. Differences at p < 0.05 were considered 
significant.  
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3.3 Results 
3.3.1 Cytotoxicity study 
3.3.1.1 Determination of Optimal number of cells per well 
As mentioned earlier, in the MTT assay, the absorbance of each well is 
dependent upon the amount of formazan formed, which is proportional to the 
number of metabolically active cells only over a limited range of cell densities 
for a fixed MTT concentration. The optimal number of cells per well needed 
therefore to be determined prior to undertaking the cytotoxicity tests. 
As seen on Figure 3-1, a linear relationship between cell number and 
absorbance was obtained up to 12500 cells/well. The absorbance leveled off at 
higher cell density. To further investigate the linear region, a third MTT assay 
was conducted, starting with a number of cells/well of 20,000 instead of 
50,000. As seen on Figure 3-2, a consistent linear relationship between 
absorbance and the number of metabolically active cells was shown over the 
range of 0-20,000 cells/well. The mid-point on the line (i.e. 10,000) was 
chosen as the optimal number of cell per well.   
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Figure 3- 1 Relationship between cell number and absorbance. Red line shows the 
linear relationship between number of cells (up to 12500) and absorbance. Arrow 
shows cell number (10,000/well) that would be used in future cytotoxicity experiments. 
Data are presented as mean ± SEM (n = 2 plates, 6 replicates per plate). 
 
 
 
 
 
 
Figure 3- 2 Relationship between cell number and absorbance. Starting cell number 
was 20,000 per well and diluted in the ratio of 1:2. Data are presented as mean ± 
SEM (n = 2 plates, 6 wells per plate). 
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3.3.1.2 MTT assay  
Once the optimal number of cells per well had been decided, a series of 
cytotoxicity experiments with FF nanotubes were carried out. The effects of 
concentrations of FF peptide, methods of FF nanotubes preparation and the 
presence of serum in the medium were tested. 
From previous published papers, it is known that the peptide monomer 
concentration can affect the size and the morphology of the nanotube 
assemblies [105]. For the study presented here, a starting peptide concentration 
of 1000 µg/ml was selected as it was the standard concentration for all other 
experiments presented in this thesis. A series of nanotube suspension dilutions 
were made according to the method described in section 3.2.2.2.2. Furthermore, 
nanotubes were also prepared by different methods and re-suspended in 
DMEM with or without serum to investigate the effect of preparation method 
and presence of serum on the metabolic activity of HeLa cells.  
 
3.3.1.2.1 Cytotoxicity of FF nanotubes prepared in HFIP/water mixture  
Figure 3-3 is a representation of the HeLa cell mitochondrial activity variation 
caused by FF nanotubes prepared in HFIP/water mixture at a starting 
concentration of 1000 µg/ml. The tube suspension was gradually diluted by a 
factor of 2 to make up a series of nanotube suspensions at different 
concentrations ranging from 1000 µg/ml to 31.25 µg/ml. As presented, the 
average percentage MTT metabolism of HeLa cells after a 24h exposure to 
nanotubes remained above 80% of that of untreated cells both in DMEM with / 
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without serum. The statistical analysis showed that none of these data was 
significantly different from the control. 
 
 
 
 
 
 
 
Figure 3- 3 Effect of dilution on the cytotoxicity of FF nanotubes made in HFIP/water 
mixture using a FF starting concentration of 1000 µg/ml. Red columns represent the 
nanotubes re-suspended in medium containing 5% serum and blue columns represent 
nanotubes re-suspended in medium without serum. Data are presented as mean ± 
SEM (n = 2 plates, 6 wells per plate). 
 
3.3.1.2.2 Cytotoxicity of FF nanotubes prepared in water alone  
To evaluate the effects of tube preparation on cellular metabolic activity, FF 
nanotubes were prepared in water alone and incubated with HeLa cells in 
DMEM with/without serum. As shown in Figure 3-4, an overall cellular 
metabolic rate above 80% was achieved for both tubes suspended in medium 
Chapter 3 Diphenylalanine nanotube-cell interactions 
  84 
with/without serum. There was no significant difference between treated cells 
and untreated controls.    
 
 
 
 
 
 
 
 
Figure 3- 4 Effect of dilution on the cytotoxicity of FF nanotubes made in water alone 
using a FF starting concentration of 1000 µg/ml. Red columns represent the 
nanotubes re-suspended in medium containing 5% serum and blue columns represent 
nanotubes re-suspended in medium without serum. Data are presented as mean ± 
SEM (n = 2 plates, 6 wells per plate). 
 
3.3.1.2.3 Cytotoxicity of FF peptide  
For comparison, MTT assay of HeLa cells exposed to FF peptide was also 
conducted and the results are presented in Figure 3-5. Cells exposed to the 
peptide in DMEM in presence or without serum retained a high mitochondrial 
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metabolism above 80%. There was no significant difference found between 
treatment groups and controls. 
 
 
 
 
 
 
 
Figure 3- 5 Effect of dilution on the cytotoxicity of FF peptide. Red columns represent 
the peptide suspended in medium containing 5% serum and blue columns represent 
peptide suspended in medium without serum. Data are presented as mean ± SEM (n = 
2 plates, 6 wells per plate). 
 
3.3.1.2.4 Cytotoxicity of 1,1,1,3,3,3- hexafluoropropan-2-ol (HFIP)  
As previously mentioned, HFIP is known to cause destruction of the mucous 
membrane in the upper respiratory tract and eyes [94] and is expected to be 
cytotoxic. The cytotoxicity of HFIP was examined on cells exposed to 
HFIP/DMEM mixture. As presented in Figure 3-6, clearly HFIP does have a 
toxic effect; there is significant toxicity in HeLa cells caused by HFIP at 
concentrations of 1%, 0.5% and 0.25% v/v HFIP/DMEM in presence of 5% 
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serum (p values  <0.0001), and at all concentrations from 1% to 0.0625% v/v 
HFIP/DMEM without serum (p values of top four concentrations are <0.0001 
and of the lowest concentration is 0.009). The percentage cellular metabolic 
activity gradually increased with further dilution of HFIP/DMEM mixture and 
at concentrations of 0.125% and 0.0625% v/v, there was no observed 
cytotoxicity to HeLa cells in presence of serum. Moreover, significant 
difference of cellular metabolic activity was found between cells with/without 
serum (p = 0.01).  
 
 
 
 
 
 
 
 
 
Figure 3- 6 Effect of diluting HFIP on the metabolic activity of HeLa cells. The 
starting concentration is 1%v/v HFIP/DMEM, same solvent concentration as in the 
1000 µg/ml FF peptide solution used to prepare the nanotubes. Red columns 
represent HFIP diluted in DMEM containing 5% and blue columns represent HFIP 
diluted in DMEM containing 0% serum. Data are presented as mean ± SEM (n = 2 
plates, 6 wells per plate). * Means significantly different from the corresponding 
control. 
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3.3.2 Scanning electron microscopy characterization of FF tubes in 
cell culture medium 
The serum used in the MTT assays was fetal bovine serum (FBS), which is a 
complex matrix containing proteins (bovine serum albumin is the major 
constituent), hormones, vitamins and some other substances [213]. As a 
control, it is essential to ascertain the stability of FF tubes in culture medium 
containing FBS. After overnight re-suspension of FF tubes prepared by both 
methods in DMEM with 5% serum, the stability of FF nanotubes was 
investigated by scanning electron microscopy characterization.  
Figure 3-7 represents a selection of SEM images taken from FF tubes (as 
prepared by both methods) in DMEM with 5% serum. Figure 3-7a is a low-
resolution SEM image of FF nanotubes prepared in HFIP/water mixture. 
Similar to previous images of nanotubes made by this type of preparation, 
close association between the tubes and projection from a common nucleation 
centre were observed. Figure 3-7b and 3-7c are high-resolution images chosen 
from different areas from Figure 3-7a. The selected nanotube portions are 
straight with a diameter that is within the normal range (427 ± 39 nm, n = 45). 
These tubes, however, were not discrete. Branching was observed as shown in 
Figure 3-7b and some thin tube-like connections between each individual tubes 
were also seen in Figure 3-7c. Figure 3-7d represents SEM image of FF tubes 
prepared in water alone. Tubes were straight, long and unbranched with no 
significant difference in morphology as compared to the previous SEM images 
of tubes prepared by this type of method (683 ± 55 nm, n = 45). The 
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background solution, i.e. DMEM with 5 % serum without nanotubes was also 
imaged, as shown in Figure 3-7e. Crystalline features were observed. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3- 7 SEM micrographs of FF nanotube re-suspended with DMEM with 5% 
serum. Figure 3-7a, 3-7b and 3-7c represent FF nanotubes prepared in HFIP/water 
mixture. Figure 3-7d represents FF nanotubes prepared in water alone. Figure 3-7e 
represents the background medium (i.e. DMEM with 5% serum alone). 
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3.3.3 Mass spectrometry 
As shown in Figure 3-3, the metabolic activity of HeLa cells exposed to FF 
tubes prepared in HFIP/water at 1000 µg/ml was observed to be above 80 %. 
On the other hand, HeLa cells exposed to 1 % v/v HFIP/DMEM (i.e. the same 
concentration of HFIP used in tube preparation) clearly had a toxic response, 
with over 90 % reduction in MTT conversion. This paradox might indicate that 
the HFIP content was somehow reduced by the evaporation process (65 ¡C 
overnight) involved in sample preparation. To confirm the conjecture made, 
mass spectrometry was performed on the samples prepared after the 
evaporation process (dried residues were re-hydrated with equal volume of 
DDH2O.).  
The mass spectra presented in Figure 3-8 were obtained under negative ion 
mode. No peaks were detected under positive ion mode, which suggested the 
detected ions were all negatively charged. The top spectrum of Figure 3-8 
represents the mass spectrum of HFIP as a control (the volume used was the 
same as the amount of HFIP used in FF tube preparation). The molecular ion 
peak of interest is 166.9828. The bottom spectrum shows the spectrum of the 
residue left after evaporation of nanotube suspension and re-hydrated with 
equal amount of DDH2O. The molecular ion peaks of interest are 311.1371 and 
166.9794, respectively. 
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Figure 3- 8 Mass spectra of (a) pure HFIP and (b) nanotubes prepared in HFIP/water 
mixture (dried and re-suspended with equal volume of DDH2O). 
 
3.3.4 Total internal reflection microscopy 
Total internal reflection microscopy (TIRM) is an important technique for 
investigating biological samples. The principle of TIRM relies on the total 
internal reflection of the incident light, which only happens when the incident 
angle is equal or greater than the critical angle. Because the refractive index is 
lower on the substrate side of the boundary, light will be completely reflected 
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[214, 215]. Comparing with normal brightfield microscopy, TIRM offers 
advantages not only in increased image contrast, but also in depth 
discrimination due to the feature of the evanescent wave generated as a result 
of the total internal reflection [214, 215]. Substances that are closely adhered to 
the substrate surface can be easily discriminated in TIRM since the light beam 
comes from the bottom of the sample, propagating through the substrate (i.e. 
glass cover slip for this experiment) then the cell media. Figure 3-9 represents 
image of a HeLa cell captured using brightfield microscopy and TIRM using 
the same objective lens and same camera. Figure 3-9a represents the brightfield 
microscopy image of a HeLa cell with size in the range of 20-30 µm. A line 
plot of the region across the cell and polystyrene coated glass surface (as 
highlighted in Figure 3-9a) is illustrated in Figure 3-9b. The intensity of the 
region is indicated by the grey value on the y-axis, and as seen from the plot 
the intensity of the cell surface and that of the glass surface do not have much 
difference with highest grey value of 165. Figure 3-9c represents the TIRM 
image of the same cell. It can be seen that TIRM image appears darker 
compared to the brightfield image, which reveals that TIRM offers better 
contrast of the same object. The same region was analyzed by line plot shown 
in Figure 3-9d. A typical distribution plot is seen that starts from low grey 
value of around 150 (the glass surface) to a broad distribution of high grey 
value at around 190 (the cell surface) and then levels off again (the glass 
surface). 
Nanotube suspension in DMEM with 10 % serum was added to the sample 
with HeLa cells attached. A time-lapse investigation was performed and TIRM 
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images were captured every 10 seconds for a time course up to 12 hours. 
Representative images are presented in Figure 3-10. Figure 3-10a is a selected 
HeLa cell (the same cell as shown in Figure 3-9) before adding nanotube 
suspension. Figure 3-10b represents the image of the same cell captured with 
nanotubes suspension added after 300 seconds. The appearance of nanotubes 
were observed, both found approaching the cell and inside of the cell (as 
indicated by the arrows). The size of the nanotubes inside the cell is around 2 
µm in length and few nanometers in width which is in the range of tube 
dimension found earlier (Chapter 2 Results, section 2.3.1.2).  Figure 3-10c is 
another example of a HeLa cell with smaller dimension (around 20 µm in 
length and 5 µm in width) before adding nanotubes. The location of nanotubes 
of lengths around 2 µm inside of the cell can be seen in Figure 3-10d at time = 
300 s (as shown by the arrows). Figure 3-10e was captured after 12 hours of 
adding nanotube suspension. No cells can be seen, i.e. no attachment of cells to 
the substrate, which is an indication of cell death. A large number of nanotubes 
with different dimensions (lengths are around few micro meters and widths are 
nanoscaled) were observed.  
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Figure 3- 9 Brightfield and TIRM images of HeLa cells. Figure 3-9a represents a 
brightfield image of HeLa cell obtained using transmitted imaging modality. Figure 3-
9b is a line plot of the region illustrated in a. Figure 3-9c represents the 
corresponding TIRM image of the same cell. Figure 3-9d is a line plot of region 
illustrated in c. 
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Figure 3- 10 Image selections from typical time-lapse TIRM movie of HeLa cells on a 
polystyrene coated coverslip with nanotube-DMEM suspension added. Figure 3-10a 
is a selected HeLa cell, Figure 3-10b represents the same cell surrounded by 
nanotubes at t = 300s (highlighted by arrows). Figure 3-10c and 3-10d represent 
another cell with intracellular nanotubes (highlighted by arrows) at t = 300s. Figure 
3-10e is an image captured after cells were dead (t = 12h, a number of small 
nanotubes were observed at the bottom of the image, with few large tubes seen at the 
top (shown by arrows). 
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3.4 Discussion 
3.4.1 Effect of diphenylalanine peptide and nanotube on HeLa cell 
cytotoxicity 
The cytotoxicity of FF nanotubes prepared in the HFIP/water mixture and in 
water alone and FF peptide was assessed on HeLa cells using an MTT assay. 
The conversion of the yellow MTT dye into purple formazan crystals was used 
to quantify cell mitochondrial activity. The results of MTT conversion 
presented in Figure 3-3, Figure 3-4 and Figure 3-5 in general are above 80%, 
which suggests the peptide-based nanotubes and the peptide itself do not cause 
any significant decrease in the cellular mitochondrial metabolism. It is known 
that the morphology of the assemblies can be altered from long tubular 
structures to other shaped nanostructures with smaller dimensions by tuning 
peptide solution parameters such as the peptide concentration, pH and 
temperature of the solvent, and the type of solvents [105, 106, 108]. The SEM 
characterization investigations in Chapter 2 (section 2.3.1.2) have shown that 
by changing the solvent type and temperature (one preparation involves 
HFIP/water mixture and the other one involves water, plus the addition of heat) 
the morphology of assembled tube is diverse (from long, discrete tubular 
structures to branched structures with nucleation centres); furthermore, as 
previously discussed in Chapter 2 section 2.3.1.4, the distribution of FF 
nanotube dimension is different by different preparations; the water-alone 
method produces slightly larger tubes with diameters mainly in the range of 
600 Ð 700 nm, whereas the tube diameter of the ones prepared in HFIP/water 
mixture mainly scaled from 200-300 nm. The high cellular metabolic activities 
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indicate that despite the differences in nanotube morphology and tube sizes, the 
cellular responses to FF tubes are similar. This finding is consistent with 
previous studies on carbon nanotubes which had shown that there was no 
variation in the observed in vitro toxicity/response of cell lines exposed to 
carbon nanotubes with different sizes [183].  
As proven by the SEM study (Figure 3-7), FF tubes are shown to be stable 
after DMEM re-suspension (with and without serum); moreover, the tubes are 
seen in solution when submerged in DMEM from the FTIR images (Figure 3-
10). The maintenance of the tube morphology may be of value in possible 
applications involving drug delivery, where maintenance of tube aspect ratio 
may improve cellular uptake [216, 217], and their incorporation into tissue 
engineering scaffolds where mechanical properties can be critical in 
maintaining structural integrity and in determining cell differentiation 
pathways [218, 219].  
The tubes made in water alone are preferred for drug delivery applications, as 
there will be a need to ensure complete removal of the toxic HFIP from tubes 
prepared by the solvent-method. In addition, the long, discrete and unbranched 
morphology (as shown Figure 3-7) may present a better value in biological 
applications. Although nanotubes prepared by both methods show encouraging 
results in the MTT assays, it should be noted that these were only preliminary 
studies and as mentioned earlier, more cytotoxicity assays, such as neutral red 
uptake and lactate dehydrogenase release assay with different cell lines are 
required in order to fully understand the cytotoxicity of FF nanotubes. 
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3.4.2 Cytotoxicity of HFIP 
HeLa cells were exposed to HFIP at the same concentration (1% v/v) as in a 
preparation of the nanotube suspension at 1000 µg/ml. HFIP showed 
significant cytotoxicity to HeLa cells at concentrations of 1% to 0.25% v/v 
HFIP/DMEM in presence of serum, and at concentrations of 1% to 0.00625% 
v/v HFIP/DMEM without serum, respectively (Figure 3-6). As HFIP is diluted, 
there was significant increase in cellular metabolic activity.  The negligible 
reduction in cell metabolic activity of the nanotubes (Figure 3-3) suggested 
there was little/no HFIP residue left by this method of preparation due to the 
overnight evaporation. This hypothesis is qualitatively confirmed by the mass 
spectroscopy study (Figure 3-8). The peak at 166.9828 in Figure 3-8a indicates 
the molecular ion peak of HFIP (molecular weight 168). It is one less than the 
molecular weight of HFIP due to the loss of one hydrogen atom. Six fluorine 
atoms act as electron-withdrawing groups, pulling electrons away from the 
central carbon. Oxygen is also an electron-withdrawing atom, which makes the 
hydrogen attached to oxygen easily to be removed, as shown in Figure 3-11. 
 
 
 
 
                     Figure 3- 11 Schematic equation of ionization of HFIP 
 
+              H + 
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The ion peak of HFIP is also detected in the nanotube sample as shown in 
Figure 3-8b (mass to charge ratio = 166.9794). Another interesting reading 
from the nanotubes rehydrated with DDH2O sample is at 311.1371, which is a 
predominated peak of almost 100% in the sample spectrum. The number is one 
less than the molecular weight of diphenylalanine (molecular weight 312). This 
result shows that there was trace of FF peptide in the nanotube suspension, 
which may be the starting material that has not self-assembled into nanotubes. 
This finding is consistent with the percentage yield of FF tubes calculated for 
both method of preparation (please refer to the supportive document), which 
showed that the yield is approximately 70.3 % for the solvent method, and 
approximately 77.2 % for the water method.  
The addition of serum in cell culture medium does not have an influence on 
cell survival rate in presence of nanotubes prepared by different methods and 
FF peptide (Figure 3-3 to Figure 3-5). One obvious explanation could be the 
tubes and peptides are naturally non-toxic to the cells in terms of metabolic 
activity. The serum, however, does have an effect on cellular metabolic activity 
when cells were incubated with HFIP (Figure 3-8). The percentage celluar 
metabolic activity of HeLa cells with serum was in general higher than that of 
the cells without serum; a significant difference was found between these two 
treatment groups (p = 0.01). Clearly serum plays a vital role in protecting cells 
from toxic HFIP. One possible explanation could be that serum proteins (e.g. 
albumin) have the ability to entrap toxic HFIP molecules via possible 
interactions such as hydrophobic interactions. Furthermore, HFIP exhibits a 
strong hydrogen bonding capacity and will associate with most molecules with 
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receptive sites such as oxygen, double bonds, or amine groups. Proteins could 
be very susceptible to bind HFIP since they have extensive amounts of 
carboxyl and amine groups. Although there is no published work on the 
interaction between HFIP and serum proteins such as albumin, some work has 
proven that bovine serum albumin has the ability to entrap other small alcohol 
molecules such as ethanol [220]. If there is binding between the serum 
components and HFIP, a reduction in toxicity would be expected, which is 
consistent with the MTT results (Figure 3-8). This finding is consistent with 
results found in cytotoxicity experiments with carbon nanotubes. After 
exposure to cells, it was found that a greater toxicity was demonstrated with 
carbon nanotubes/nanoparticles in the absence of serum, indicating a protective 
effect of serum on cells and significant interaction between serum and carbon 
nanotubes/nanoparticles [195, 197]. 
 
3.4.3 HeLa cell characterization by total internal reflection 
microscopy (TIRM)  
The aim behind this study was to investigate HeLa cell behaviour when 
surrounded by an extracellular environment occupied with FF nanotubes. 
Cellular behaviour at interfaces is important for many applications including 
drug delivery. The ability of cells to uptake liposomes or biodegradable 
nanostructures such as peptide nanotubes [221] or to be used as cages for 
monodispersed nano-sized drug delivery system [222] offers the opportunity 
for targeted delivery. In order to access these delivery systems, the interaction 
Chapter 3 Diphenylalanine nanotube-cell interactions 
  100 
between cells and drug carriers has to be studied to assure structural stability 
and successful delivery.  
The technique adopted in this investigation is total internal reflection 
microscopy (TIRM) which is known as a high resolution live cell imaging 
technique that has been utilized for studying cells at interface [223]. The major 
advantages of TIRM over other microscopic or spectroscopic techniques 
include the allowance of free motion of cell/particle under the influence of all 
forces acting on them, increased image contrast, and the fact there is no need to 
label particles/cellular structures [223].  
The images presented in Figure 3-9 were captured of the same HeLa cell using 
different imaging techniques, i.e. brightfield imaging using the transmitted 
light function of camera (Figure 3-9a) and TIRM (Figure 3-9c), respectively. 
Clearly from the comparison between these images, TIRM offers a more in 
depth characterization due to the nature of evanescent illumination. One thing 
that needs to be taken into consideration when choosing TIRM as the technique 
to study cells adhered to a substrate is the substrate thickness and roughness. 
The substrate thickness needs to be within the range of the evanescent wave 
penetration depth (which is normally around 100-200 nm) otherwise it will not 
be visible by TIRM [215]. Roughness of the substrate is another key parameter 
in TIRM imaging as scattering of the evanescent field will occur if the 
substrate surface is too rough [214]. Based on these considerations poly-lysine 
was therefore the chosen polymer to be coated onto the glass cover slip to 
promote cell adhesion in this study because of two reasons: firstly, poly-lysine 
has a molecular weight in the range of 75,000 Ð 100,000 and can be 
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homogenously distributed on glass cover slip with a coating thickness of a few 
nanometers; and secondly it exhibits a low surface roughness (root mean 
square value = 0.35 nm), which clearly is an order of magnitude smaller than 
the evanescent wave penetration depth [224]. Nevertheless, despite the 
drawbacks of TIRM, it still presents the advantage of a more in depth 
discrimination compared to normal brightfield images (as shown in Figure 3-9); 
the image quality and resolution in terms of intensity variation of the images 
(Figure 3-9a and Figure 3-9c) are evidently presented in Figure 3-9b and 
Figure 3-9d. 
Dynamic information of cells with influences of all forces and on the 
interaction between cells and the surrounding extracellular environment can 
also be achieved using TIRM with high-speed time-lapse imaging. Video-rate 
imaging was applied on HeLa cells in presence of nanotube suspension (please 
refer to supporting documents). Clearly from the videos, nanotubes underwent 
free diffusion in extracellular bulk medium; The HeLa cell membrane 
reorganized with retraction and expansion motions in response to nanotube 
approaches. This result is consistent with previous experiments done on 
fibroblast cells with TIRM imaging after exposure to sub-micron sized 
polymeric particles [225]. The cell membranes were found to be re-organized 
and lamella protrusion and retraction also played a key role in fibroblast 
locomotion from the TIRM time-lapse imaging.  
The series of images presented in Figure 3-10 are representative images taken 
from a time-lapse investigation of HeLa cells immersed in FF nanotube 
suspension; the images of cells with nanotubes presented were taken at time = 
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300 s after adding nanotube suspension (Figure 3-10b and Figure 3-10d). 
Nanotubes with dimensions that were less than 20 µm in length and few 
nanometers in width were seen outside of the cells. Moreover, short nanotubes 
with length of about 2-3 µm were appeared to be uptaken by the cells (Figure 
3-10c and 3-10d). According to the physicochemical characteristics of the 
nano-carriers, there are several cellular uptake pathways in general, and 
depending on the nature of the target cell and different mediators, they can be 
classified into clathrin-mediated endocytosis, caveolae-mediated endocytosis, 
macropinocytosis, and phagocytosis [226]. The cell of interest in this study, i.e. 
HeLa cell is human cervical cancer cell and therefore it is not phagocytotic 
since this process is only accomplished by specialized cells such as 
macrophages, monocytes and neutrophils. A key factor in determining cell 
uptake pathway, besides the nature of the cell, is the size of drug carrier [226]. 
Caveolae are small flask-shape pits of approximately 50 nm in diameter; 
clathrins form vesicles of approximately 100 nm in diameter [227]; 
macropinocytosis is the process by which molecules of the largest size are 
internalized, the diameter range of the vesicles formed is from 0.5 Ð 5 µm 
[228]. The tubes found inside of HeLa cells in Figure 3-10 were about 2 µm in 
length and few nanometers in width. Macropinocytosis may be the cellular 
uptake pathway of these small FF tubes. Nevertheless, the dimension of FF 
nanotubes is very diverse; the length ranged from few micrometers to more 
than 1000 µm. Only tubes with lengths shorter than 5 µm may qualify for this 
process and larger tubes (as for the ones shown in Figure 3-10c and 3-10d) 
were only observed outside the cells. It should be pointed that the TIRM 
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experiments presented here were only preliminary, in order to fully understand 
the celluar uptake mechanism, a large quantity of experiments are required.  
Cell death was observed after 12 hours of nanotube exposure (Figure 3-10e). 
This was considered to be a result of the experimental conditions for several 
reasons. Firstly, cells are unlikely to survive at room temperature (~ 20 ¡C), 
atmospheric N2/O2 ratio (~ 78 : 21), and presence of debris for a long period. 
Secondly, the MTT assays applied on HeLa cells have shown high cell 
viability after 24 hours nanotube incubation. Finally, cell death was also 
observed in untreated cells after 12 hours. 
It is an important finding that small FF tubes were found inside of living cells 
in respect of the potential in drug delivery as drug carrier. Although small 
molecules can pass through cell membrane easily via simple diffusion, there is 
a number of therapeutic drugs that may need carriers in order to be taken up by 
cells, one example is nucleic acids which are unable to cross the cell membrane 
[229]. FF nanotubes are non-toxic in terms of cell metabolic activity and can 
be taken up by living cells, which are important findings for their future 
pharmaceutical applications. 
 
3.5 Conclusions 
The studies presented in this chapter focused on the investigation of the 
cytotoxicity of FF nanotubes prepared either in HFIP/water mixture, or in 
water alone. In general, the performed MTT assays have revealed that the 
nanotubes and FF peptide did not cause any mitochondrial related damage to 
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HeLa cells. Interestingly, cells were observed to uptake short tubes with a 
length around 2 µm through a suggested macropinocytosis pathway. Moreover, 
the toxic HFIP used in the sample preparation was found removed by the 
evaporation process. HFIP on its own has shown a highly toxic effect on HeLa 
cells with over 90% decrease in cell metabolic activity. Although FF tubes 
prepared by both methods present encouraging results from these studies, more 
cytotoxicity assays with different cell lines are needed to evaluate the cytotoxic 
property of FF nanotubes. Nevertheless, these observations clearly do not rule 
out potential applications of FF nanotubes in the pharmaceutical and 
biomedical areas. 
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Chapter 4 Evaluation of the Potential of 
Diphenylalanine Nanotubes as a Drug Carrier 
 
4.1 Introduction 
In previous chapters, detailed characterization of FF peptide nanotubes using a 
variety of microscopic and spectroscopic techniques such as AFM, SEM, and 
Raman, plus cell-based investigations such as the MTT assay and TIRM 
imaging have been presented. Based on the knowledge obtained, the work 
presented in this chapter focuses on the investigation of the potential of FF 
nanotubes as a carrier in drug delivery.  
As mentioned in Chapter 1, many efforts have been made to investigate the 
biological potential of FF-based nanostructures [78, 118, 136, 141, 212]. Due 
to their physical and chemical properties, research into FF-based assemblies 
has grown at an accelerating pace in recent years [138, 145]. A number of 
published studies have demonstrated their potential, including for cell growth 
support in 3D cell culture [230], as part of a novel biosensing platform for 
enzyme-biosensor applications [131], and to enhance the performance of 
carbon nanotube-based nano-electronic devices [164].  
In order to evaluate a FF nanotube-based drug delivery system, several criteria 
need to be understood: first, the physical, chemical properties of the carrier; 
second, the biocompatibility of the carrier; third, the stability of the drug-
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loaded FF nanotube whilst in vitro and in vivo; and important parameters 
regarding the pharmacodynamic and pharmacokinetic profile of the release in 
vivo. There is little information published on peptide nanotube-based drug 
delivery system despite the apparent advantages it can offer, such as 
biocompatibility, biodegradability, ease to fabricate and low cost. The aim of 
the work presented in this chapter is to synthesize and characterize drug-loaded 
FF nanotubes and evaluate their potential in drug delivery applications by 
conducting in vitro dissolution experiments.  
 
4.2 Experimental 
4.2.1 Materials 
Agents used in drug/tube synthesis and dissolution study were purchased from 
Sigma-Aldrich including diphenylalanine peptide (FF), 1,1,1,3,3,3- hexafluoro-
2-propanol (HFIP), salicylic acid (SA), 5-fluorouracil (5FU), ethanol, dimethyl 
sulfoxide (DMSO), and phosphate buffered saline (PBS).  
 
4.2.2 Method  
4.2.2.1 FF tube synthesis 
As mentioned earlier, FF tubes prepared in water alone are perferred for 
biological and pharmaceutical applications because of the absence of HFIP as 
well as the maintainance of structural integrity in presence of buffers, such as 
PBS. FF tubes were synthesized as previously described: lyophilized FF 
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peptide was mixed with ddH2O at 65 ¡C for thirty minutes, suspensions were 
then left to cool to room temperature. 
 
4.2.2.1.1 SA-FF tube synthesis 
For investigation of the effect of salicylic acid concentration on tube formation: 
SA powder was dissolved in a mixture of 1:9 ethanol/ddH2O with different 
quantities to make up a series of concentrations:  2mM, 1mM, 0.5mM, and 0.2 
mM. One part of SA solution was mixed with one part of FF tube suspension 
with 30 seconds vortex mixing and 24 hours incubation. 
To study the effect of solvent on tube formation: SA powder was dissolved a 
mixture of ethanol: ddH2O with varied ethanol content, ranging from pure 
ethanol, 1:1 ethanol/water, 2:3 ethanol/water, 1:4 ethanol/water and 1:9 
ethanol/water. The concentration of SA was fixed at 0.2 mM. Again, equal 
volumes of SA solution were mixed with FF tube suspension and vortex mixed 
for 30 seconds and then incubated for 24 hours. 
For the dissolution test and other characterization analysis including XRPD 
and UV-Visible spectroscopy experiments, SA solution used in sample 
preparation was 0.2mM and the solvent was 1:9 ethanol/water. 
 
Chapter 4 Diphenylalanine nanotubes as a drug carrier 
  108 
4.2.2.1.2 5FU-FF tube synthesis 
To investigate the effect of 5FU concentration on tube assembly, 5FU was 
dissolved in 1:9 DMSO/ddH2O with different quantities to make a final 
solution of 1mM, 0.4 mM, 0.2 mM and 0.1 mM. Next, equal volumes of 5FU 
solution were mixed with freshly prepared FF tube suspension and vortex 
mixed for 30 seconds. Samples were kept for 24 hours at room temperature. 
For other experiments including dissolution testing, XRPD and UV-Visible 
spectroscopy, 0.1mM was chosen to be the optimal concentration for 5FU 
solution. 
 
4.2.2.2 SEM characterization  
Samples of drug-mixed, drug-free nanotube and pure drug dissolved in 
corresponding solvents were placed on freshly cleaved mica substrates (Agar 
Scientific Ltd., Stansted, UK), and gently air-dried. The mica substrates were 
then mounted onto 12 mm aluminium sample stubs (Agar Scientific Ltd.) using 
carbon tabs (12 mm diameter, Agar Scientific Ltd.). The samples were then 
coated with a thin layer of gold to facilitate imaging (argon gas with an ion 
current of 30 mA). SEM images were recorded using a JSM JEOL 6060 SEM 
(JEOL, Tokyo, Japan) operating at 10 kV. The size of the tubes was measured 
using SM-35080 SMILE VIEW software. 
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4.2.2.3 UV-Visible spectroscopy 
The UV-Vis spectra of both pure drug sample and drug/tube mixtures were 
obtained on a Cary 50 UV-Vis spectrophotometer (Varian Inc.). In order to 
find the wavelength of maximum absorbance, a whole wavelength scan was 
performed on both drug samples (3 ml) at a wavelength range from 200 nm to 
400 nm.  
 
4.2.2.4 Powder X-ray diffraction 
XRPD measurements were recorded on a Bruker D8 (Bruker, Coventry, UK). 
Dried samples of drug-free FF tubes and drug/FF tubes mixtures were loaded 
into glass capillaries (0.7 mm, Capillary Tube Supplies Ltd.). Data were 
collected in step scan mode between 2.0¡ and 90¡ (2θ) with a step size of 1¡ 
and a counting time of 10 s/step. The working conditions were 10 kV and 30 
mA. All peak positions were used for the determination of micro structural 
parameters.  
 
4.2.2.5 Percentage drug loading 
After being incubated for 24 hours, drug/FF tubes mixtures were centrifuged at 
10,000 rpm for 5 minutes. The concentration of drug remaining in the 
supernatant after centrifugation was measured at 296 nm and 266 nm, which 
are the maximum absorbance wavelengths as determined by previous UV-Vis 
spectroscopy study for SA and 5FU, respectively. The percentage drug loading 
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was calculated by subtracting the amount of drug in the supernatant from the 
total amount used, and then dividing by the total amount of drug used. 
 
4.2.2.6 Dissolution study 
The in vitro release of SA and 5FU from FF nanotubes was determined by the 
dialysis method. Samples of drug/tube mixtures and free drug powder were 
loaded into hard gelatin capsules (100 mg) with glass beads. 3 cm of dialysis 
tube (MWCO 2000, Sigma-Aldrich) was cut-off and placed under ddH2O for 
24 hours. Both the inside and outside of the membrane were washed several 
times to remove impurities. Both ends of the membrane were closed with tied 
knots, and then this was placed in PBS (0.1M, pH 7.4) for 1 hour. The prepared 
drug samples were enveloped in the pre-treated dialysis membrane and air 
bubbles were removed before sealing the dialysis bag. The dialysis membrane 
was then immersed in a 200 ml beaker containing 100 ml of PBS (0.1 M, pH 
7.4) and with a stir bar placed at the bottom. The beaker was placed in a water 
tank with a set temperature at 37 ¡C. The dissolution experiment was 
performed for 2 hours; aliquots of samples (3 ml) were taken out at 
predetermined time points; the same amount of fresh medium was replaced 
into the beaker immediately at each time. Samples were analyzed using the 
UV-Vis spectrophotometer at an appropriate wavelength (296 nm for SA and 
266 nm for 5FU). For comparison, the release of pure drug from hard gelatin 
capsule loaded with glass beads was also conducted. All of the experimental 
conditions were kept the same for parallel comparison.     
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4.3 Results 
4.3.1 Background: choosing a drug candidate 
Choosing an appropriate drug is the first step to study the potential of FF 
nanotubes as drug-carrying vehicle. The candidate should have a molecular 
structure that is capable of forming interactions with FF nanotubes and ideally 
a well-characterized drug so that the in vitro release profile can be compared 
with previous delivery systems. A molecular representation of FF nanotubes is 
shown in Figure 4-1 [97]. As presented in the figure, the nanotube consists of 
extensive π-π interactions and H-bonding between each adjacent peptide; 
therefore an ideal drug should have an aromatic ring and a hydrogen 
donor/acceptor group that is capable of forming π-π interactions and H-
bonding with the FF tube. Based on these considerations, two drug candidates 
were selected: salicylic acid and 5-fluorouracil (Figure 4-2). These two drug 
molecules have a planar structure with an aromatic ring and polar groups such 
as hydroxyl, carbonyl and cyclic amide groups that perfectly fit into the 
expected structure of an Ôideal drugÕ for FF tube. Furthermore, these drugs are 
well known molecules that have been studied for many years; salicylic acid 
(SA), is the precursor for aspirin, and is widely used in organic chemistry and 
in small quantities it can be used in acne treatment and as a food preservative 
[231]; 5-fluorouracil (5FU) is an anti-cancer drug that was discovered and 
synthesized by Charles Heidelberger in 1957, and is a clinically important drug 
in treatment of colon cancer and pancreatic cancer [232]. These drug 
candidates have been studied with a variety of delivery system, including 
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polymer-based matrix/films/microspheres/microfibers, peptide and lipid 
hydrogels, and tablets [233-237]. 
 
 
 
 
 
 
 
 
 
Figure 4- 1 Molecular model of FF nanotube. Figure 4-1a is a constructed model of a 
FF nanotube with a 110 nm outer diameter and a 50 nm inner diameter; Figure 4-1b 
is an enlarged section as highlighted by the rectangle shown in (a). The atoms 
constituting the pore are presented using a space-filling illustration. As shown by the 
detailed view, the pores of the FF tube are composed of peptide bonds with H-bonding 
between adjacent peptide backbone, the aromatic rings orientate outside forming 
extensive π-π interactions [97]. 
 
 
 
 
Figure 4- 2 Molecular structures of salicylic acid (left), 5-fluorouracil (middle), and 
diphenylalanine comprising the L-isomer of phenylalanine (right). 
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4.3.2 Characterization of salicylic acid/diphenylalanine nanotube 
mixtures  
Samples of FF nanotubes mixed with SA were characterized using SEM, UV-
Visible spectroscopy, and XRPD.  
 
4.3.2.1 SEM 
As mentioned in previous sections, several factors are known to have influence 
on the formation of self-assembled FF nanotubes [105, 106]. The investigation 
presented here focuses on the effect of solute concentration and choice of 
solvent on the formation of FF tubes. The morphology of FF nanotube mixed 
with SA at various concentrations and percentages of ethanol content was 
observed under a scanning electron microscopy. Apart from the two variables, 
other experimental parameters were kept constant, such as FF peptide 
concentration (1 mg/ml), and SEM instrument parameters.  
 
4.3.2.1.1 Different salicylic acid concentrations 
The SEM micrographs presented in Figure 4-3 are images of samples prepared 
by mixing freshly prepared FF nanotubes solution with SA solution (dissolved 
in 1:9 ethanol/water) with different concentrations, ranging from 2 mM to 0.2 
mM (Figure 4-3a to Figure 4-3d), and aged for 1 day before being air-dried. 
The morphology of the self-assemblies varies with different SA content; few 
needle-like formations were found at the highest SA ratio (Figure 4-3a) with 
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length around 20 µm. As SA content was reduced by an order of magnitude of 
2, fibril-like structures were observed in Figure 4-3b with length of more than 
100 micrometers and widths less than a micron. As SA concentration was 
further reduced, a network of tubes and fine fibrils were found (Figure 4-3c) 
with the diameter of the tubes around 1 µm. Finally, the sample formed by 
mixing FF tubes with 0.2 mM SA solution presenting long, uniformed and 
discrete tubes of similar dimension and morphology to bare FF tubes (Figure 4-
3d and 4-3f), the average diameter is 1.8 ± 0.3 µm and lengths are up to several 
hundred of microns (n = 35). Pure SA crystals were also prepared and 
presented in Figure 4-3e. The needle-like morphology is consistent with 
previous published studies on the crystal morphology of SA [238]. Because of 
the obtained size uniformity and lack of excessive SA crystals, 0.2 mM SA 
solution was therefore used in the all sample preparations for the dissolution 
study and other characterization analysis (unless indicated) presented in this 
chapter. 
 
4.3.2.1.2 FF assembled in different ethanol percentages  
SEM micrographs of FF nanotubes mixed with 0.2 mM salicylic acid solution 
of various ethanol content are illustrated in Figure 4-4. Five different 
proportions were chosen by varying the ratio between ethanol and water, 
ranging from pure ethanol (i.e. FF peptide was dissolved in HFIP with ethanol 
dilution in absence of water) to ethanol/water = 1: 9. Since the amount of SA 
used in preparing these samples was the same, any differences in tube 
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morphology observed in Figure 4-4 were solely as a result of the change of the 
solvent. A network of gel-like structures and drug crystals were observed at 
100 % and 1:1 ethanol/water (Figure 4-4a and 4-4b). No tubes were observed, 
and compared with the needle-shaped pure SA crystals presented in Figure 4-
3e, it was found that the presence of FF peptide and water strongly influences 
the morphologies of the resultant SA crystals. While increasing the water 
content to ethanol/water = 2:3 (Figure 4-4c), leaf-like SA crystals appeared 
with an average width of 8.7 ± 0.8 µm and an average length of 103 ± 5.1 µm 
(n = 35). FF fibrils/tubes were only observed at ethanol/water = 1:4 or below 
(Figure 4-4d and 4-4e). Fine fibrils with a feather-like morphology were 
present at ethanol/water = 1:4, with average width 320 ± 18 nm and the lengths 
up to hundreds of micrometers (n = 35). When the water content was the 
highest (ethanol/water = 1:9), well-formed tubes with diameters around 1.4 ± 
0.8 µm and micrometer lengths were present (n = 35).  
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Figure 4- 3 SEM micrographs of FF nanotubes mixed with SA. SA is dissolved in a 
mixture of ethanol to water = 1:9 with various concentrations (a) 2mM, (b) 1mM, (c) 
0.5mM, (d) 0.2mM; SA crystals (dissolved in ethanol) are presented in 4.3e; bare FF 
nanotubes in ethanol/water =1:9 without SA loaded is presented in 4.3f.  
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Figure 4- 4 SEM micrographs of FF nanotube/SA mixtures formed in different ethanol 
percentage. Ethanol to water content is varied from (a) pure ethanol (b) 1:1, (c) 2:3, 
(d) 1:4 and (e) 1:9. The SA solution used to prepare these samples was 0.2mM. 
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4.3.2.2 UV-Visible spectroscopy 
UV-Vis spectra of FF nanotubes mixed with SA, and of free SA are presented 
in Figure 4-5. As shown in the spectra, the peaks associated with SA are shown 
at 297.2 (Figure 4-5a) and 294.9 nm (Figure 4-5b). Both values are close to the 
reference value of SA (296 nm) showing a good accuracy [238]. The peak at 
wavelength 255.1 nm was attributed phenylalanine. The peak at 229.9 nm was 
another peak related to SA, which is missing in Figure 4-5a, probably due to 
the broadening of the phenylalanine peak. For the drug release experiment, 
dissolution samples were analyzed using the standard wavelength of SA, which 
is 296nm.   
 
 
 
 
 
 
 
 
Figure 4- 5 UV-Vis spectra of FF nanotube/SA and free SA. (a) FF tubes mixed with 
SA (0.2mM), and (b) SA alone. Peaks of interest are labelled.  
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4.3.2.3 Powder X-ray diffraction 
To further characterize SA/FF nanotubes mixtures, XRPD was performed on 
dried samples of the mixtures. The patterns presented in Figure 4-6 were 
obtained from FF nanotubes (Figutr 4-6a) and nanotubes with SA (Figure 4-
6b). There is little/no difference observed between the two patterns.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4- 6 XRPD patterns of FF nanotubes with and without SA. (a) drug-free FF 
tubes, and (b) SA-mixed FF tubes (0.2mM). 
 
4.3.2.4 Salicylic acid loading capacity 
The observed relationship between SA loading capacity and the concentration 
of SA solution is presented in Figure 4-7. FF solution of a fixed concentration 
(1mg/ml) was mixed with SA dissolved in ethanol: water (1:9) mixture with 4 
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different concentrations. After 24 hours incubation, the drug content was 
shown to increase rapidly from 0.41 % to 3.67 % as the concentration of SA 
solution is increased from 0.1 mM to 0.5 mM; further increase in concentration 
from 0.5 mM to 1 mM has little effect on % loading (drug content is 4.00% at 
1 mM), which indicated a possible SA loading limit for FF tubes. This 
suggestion is supported by SEM analysis (Figure 4-3); the morphology of FF 
tubes changed from tubular to fibillar as SA concentration was increased with 
eventually no tubes being formed, which may indicate a possible influence of 
SA on FF tube self-assembly.   
 
 
 
 
 
 
 
       Figure 4- 7 Loading capacity of FF nanotubes as a function of SA concentration. 
 
4.3.3 In vitro release of salicylic acid from diphenylalanine nanotubes 
SA-loaded FF nanotubes were prepared in hard gelatin capsules for in vitro 
dissolution experiment, the weight of the drug-loaded capsule was 100 mg 
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±3.8. The bulk medium used was 0.1 M PBS (pH 7.4) at 37 ¼C. Calibration of 
the UV to SA concentration was performed prior to the dissolution experiment. 
Five consecutive points of concentration were chosen and the data is plotted in 
Figure 4-8. The linear relationship presented between the concentration and the 
absorbance indicates a good level of linearity of the measurement (correlation 
coefficient = 0.999).  During the dissolution, aliquots of the sample solution (3 
ml) were taken at regular time interval (fresh medium was replaced into the 
beaker) and analyzed by UV-Vis spectroscopy at a wavelength of 296nm (as 
mentioned earlier, 296nm was used as the standard wavelength for SA). The 
experiment was repeated three times. The cumulative percentage release of SA 
from FF nanotube was studied and compared with that of free SA. Figure 4-9 
represents the release curve of both free SA and tube-bound SA over a period 
of 2 hours. For free SA an initial rapid release was completed within a short-
time period of about 10 minutes rapidly reaching over 80% release. FF tubes 
with SA showed a slight extended release with 77% released after 40 minutes.  
 
 
 
 
 
                                        Figure 4- 8 Calibration line of SA 
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Figure 4- 9 Cumulative percentage release of salicylic acid with and without 
incorporation of FF nanotubes. The blue curve represents free SA release; the red 
curve represents FF tube-bound SA release. Data is presented as mean ± SEM (n=3). 
 
4.3.3.1 Release model 
Various models were applied to interpret the release process of salicylic acid 
from FF nanotube, including zero-order kinetic model, first-order kinetic 
model, Higuchi model and Korsmeyer - Peppas model [239]. 
The zero-order rate (Equation 4.1) describes a system where the drug release 
rate is independent of its concentration, where Q is the amount of drug released 
in time t, Qo is the amount of drug present at t = 0, and ko is zero-order rate 
constant expressed in units of concentration/time [239]. The kinetic is plotted 
as a function of cumulative percentage release of drug against time (Figure 4-
10). 
Q =Qo + kot                                             (4.1) 
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As presented, when describing the release of SA from FF tubes using zero 
order model, the release shows a two-phased pattern: the first 50% SA release 
shows a good linear relationship with a correlation coefficient (R2) of 0.988. 
As more SA is being released, the slope of the line changed; the second part of 
the release can no longer be best described as zero order kinetics as the R2 
value drops to 0.844 which is relatively low. 
 
 
 
 
 
 
                        
                       Figure 4- 10 Zero order release model of SA/FF nanotube. 
 
The first-order model describes release from a system where release rate is 
concentration dependent (Equation 4.2), where Q∞ is the total amount of drug 
in the matrix initial concentration of drug and k1 is a first order constant [239]. 
By rearranging Equation 4.2, it can be expressed as the natural logarithm of the 
cumulative percentage of drug remaining versus time, i.e. Ln (Q∞ - Q)=k1t, 
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where Q∞ - Q is the amount of drug remaining (Figure 4-11). Similar to the 
previous model, the figure still presents two distinct sections; one starts from t 
= 0 to t = 4 mins with a drug release up to 50 %, followed by a second phase 
with a different calculated equation and rate constant as the dissolution 
progresses. Compared to the data obtained from the zero order release, the first 
order model gives a slightly higher R2 value of 0.995 for the first 50 % release, 
but a better R2 value of 0.901 for the release from 50% to 80%. 
Q = Q∞ (1+e
-k
1
t
)                                    (4.2) 
  
 
 
 
 
 
                    Figure 4- 11 First order release model of SA/FF nanotube. 
 
Figure 4-12 represents the data presented using the Higuchi model which 
describes the release of a drug from an insoluble matrix as a square root of time 
dependent process based on Fickian diffusion (Equation 4.3), where kH is the 
Higuchi rate constant [239]. The R2 values of the two-phased drug release 
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pattern are 0.939 and 0.912, respectively.  
Q = kHt 
½
                                               (4.3) 
 
 
 
 
 
 
 
                Figure 4- 12 Higuchi release model of SA/FF nanotube. 
 
The final model used to study the release kinetics was Korsmeyer - Peppas 
model which describes drug release from a polymeric system (Equation 4.4) 
[239]. The first 60% of drug release data was fitted in Korsmeyer Ð Peppas 
model (Figure 4-13).  
Q / Q∞ = kt
n                                                              
(4.4) 
Where Q / Q∞ is fraction of drug released at time t, k is the rate constant and n 
is the release exponent. The n value is used to characterize different release 
mechanisms for cylindrical shaped matrices. For n = 0.45, the release kinetics 
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is controlled by Fickian diffusion mechanism; for n =0.89, the process is 
described as a case II transport; if 0.45 < n < 0.89, it is a non-Fickian diffusion 
(i.e. mixture of Fickian and Case II diffusion); and for n > 1, the process is 
considered as a super case II transport [239]. For the present study, the n values 
for the first 50% drug release is 0.914, indicating the mechanism of release 
starts as a non-Fickian diffusion. The second phase drug release has an n = 
0.282, which is beyond the theoretical lowest value of n (0.45). The possible 
reasons for this will be discussed in the discussion section. 
 
 
 
 
 
 
 
               
              Figure 4- 13 Korsmeyer - Peppas release model of SA/FF nanotube. 
 
A detailed discussion regarding the release mechanisms will be presented in 
later sections. A summary of all models with calculated equations and 
corresponding R2 values is presented in Table 4.1. 
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                Table 4. 1 Release models and parameters of SA/FF nanotubes. 
Sample: SA incorporated with FF nanotubes 
Kinetic 
Model 
 
Mathematical 
equation 
 
Calculated equation 
Correlation 
coefficient 
Zero-order Q =Qo + kot 
Q = 9.77 t +1.56 
Q = 0.576 t +55.96 
0.988 
0.844 
First-order Q = Q∞ (1+e
-k
1
t) 
   Ln(1-Q/ Q∞)=-0.126t+ 4.608 
Ln(1-Q/ Q∞)=-0.017t+ 3.809 
0.995 
0.901 
Higuchi Q = kHt 
½ 
Q = 19.52t1/2 Ð 3.202 
Q = 5.105t1/2 + 46.12 
0.939 
0.912 
Korsmeyer
-Peppas 
Q / Q∞ = kt
n 
 
LogQ=0.914Logt+1.055 
LogQ=0.282Logt+1.533 
0.995 
0.993 
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4.3.4 Characterization of 5FU-loaded diphenylalanine nanotube  
Similar to the experiments performed on SA-loaded FF tubes, samples of FF 
nanotube with 5FU were characterized using SEM, UV-Visible spectroscopy, 
and XRPD.  
 
4.3.4.1 SEM characterization of diphenylalanine nanotube with different 
5- fluorouracil concentrations 
Samples of 5FU-loaded FF nanotubes were prepared by mixing freshly 
prepared FF nanotube suspension with 5FU (dissolved in DMSO/water = 1:9) 
solution of different concentrations ranging from 0.1mM to 1mM. All 
characterization analysis was performed on air-dried samples (aged for 1 day) 
and the SEM micrographs of 5FU-loaded nanotubes are presented in Figure 4-
14. Two controls were performed: SEM imaging of 5FU alone (Figure 4-14e) 
and FF tubes formed in the solvent without 5FU (Figure 4-14f). The image 
shown on the top left (Figure 4-14a) presents samples of FF tubes incorporated 
with 5FU at highest concentration: 1mM. Incomplete tubes were observed with 
pieces lined up. Figure 4-14b shows FF tubes with a reduced concentration of 
5FU (0.4mM); fewer fragments were presented as compared with the higher 
concentration, nevertheless there were still portions of tubes observed. As the 
concentration of 5FU solution was further reduced to 0.2mM, more and more 
intact tubes were observed (Figure 4-14c). The circled highlights show the few 
broken tube pieces observed. Finally, at 0.1mM, the 5FU-loaded tubes appear 
to be long and intact with a diameter of 1-2 µm and a length up to hundreds of 
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micrometers (size measurement was performed on large number of tubes, n = 
90. The experimental procedure was referred to the method listed in Chapter 2). 
For latter experiments, unless otherwise indicated, 0.1mM was chosen to be the 
fixed concentration of 5FU solution in all sample preparations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4- 14 SEM micrographs of FF nanotubes loaded with 5FU. 5FU is dissolved in 
a mixture of DMSO in water with a ratio of 1:9 with various concentrations (a) 1mM, 
(b) 0.4mM, (c) 0.2mM, (d) 0.1mM; image of 5FU alone is presented in 4-14e; bare FF 
nanotubes in DMSO/water = 1:9 without 5FU loaded is presented in 4-14f. 
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4.3.4.2 UV-Visible spectroscopy 
UV-Vis spectroscopy was applied to samples of 5FU-loaded nanotubes and 
pure 5FU over a wavelength from 200 nm to 400 nm. As shown in Figure 4-15, 
a broad peak at 266 nm was observed for the spectrum of 5FU (Figure 4-15b), 
which is consistent with the published UV-Vis spectrum of 5FU [240]. On the 
other hand, the spectrum of 5FU-loaded FF tubes presents two characteristic 
peaks, one observed at 254 nm which was also found in the spectrum of SA-
loaded FF tubes; and the other one was shown at 267 nm. For the 5FU release 
experiment, dissolution samples were analyzed at 266 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4- 15 UV-Vis spectra of FF nanotube/5FU and free 5FU. (a) FF tubes loaded 
with 5FU, and (b) spectrum of 5FU alone. Peaks of interest are presented. 
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4.3.4.3 Powder X-ray diffraction 
Similar to the previous XRPD experiment applied on FF tubes and FF tube/SA 
mixture, samples of FF tubes with and without 5FU loaded were analyzed by 
XRPD to identify differences regarding the molecular arrangement of FF tubes. 
The patterns are presented in Figure 4-16 with the spectrum representing 5FU-
loaded tubes shown in 4-16a and the spectrum representing tubes alone shown 
in 4-16b. The two patterns show little or no difference with good alignment, 
indicating that the molecular packing of the tubes with or without drug was 
similar.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4- 16 XRPD patterns of FF nanotubes with and without 5FU loaded. (a) drug-
free FF tubes, and (b) 5FU-loaded FF tubes. 
 
 
Chapter 4 Diphenylalanine nanotubes as a drug carrier 
  132 
4.3.4.4 5-fluorouracil loading capacity 
In order to search for the influence of 5FU concentration on the drug loading 
capacity of FF tubes, samples of tube suspensions were mixed with 5FU 
solution with different concentrations ranging from 0.1mM to 1mM. As shown 
in Figure 4-17, when the concentrations of 5FU solution increases from 0.1 to 
0.4mM, the drug content increases rapidly from 0.82 % to 3.34 % after 24 
hours incubation time. The percentage rise in drug loading slows down with 
further increase in 5FU concentration; at 1 mM the drug content is 3.59 %. 
This finding is consistent with that of the SA loading capacity (Figure 4-7), 
which may indicate a possible saturation loading of the FF tubes before their 
assembly is unduly affected. Again, the SEM imaging of FF tubes loaded with 
5FU with different concentration confirms this suggestion; FF tubes appeared 
to be disassembled at high 5FU content (Figure 4-14).    
 
 
 
 
 
 
Figure 4- 17 The loading capacity of FF nanotubes as a function of 5FU 
concentration. 
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4.3.5 In vitro release of 5- fluorouracil from diphenylalanine 
nanotubes 
A dissolution study was carried out with FF tubes loaded with 5FU; dried 
samples of drug-loaded tubes were prepared in hard gelatin capsule (weight of 
the drug-loaded capsule is 100 mg ±5.7). The medium used was PBS (0.1 M, 
pH 7.4) at 37 ¡C and the experiment was repeated three times. Samples of pure 
5FU loaded capsules were also prepared and their release was compared with 
that of the tube-drug mixture. Calibration of 5FU was performed prior to the 
experiment and is shown in Figure 4-18. Five points of concentration were 
chosen and the corresponding absorbance was measured at 266 nm (i.e. the 
max. absorbance wavelength as determined from the previous UV-Vis 
spectroscopy spectrum of 5FU). The calibration appears linear with a 
correlation coefficient of 0.999. The in vitro dissolution of 5FU released from 
FF tubes was compared with that of the free drug. Cumulative percentage 
release of 5FU over a period of 2 hours is presented in Figure 4-19. The release 
of free drug appears to be rapid; it reaches over 80% within first 10 minutes 
and remains around 80 %. In contrast, the release of drug from FF tubes 
presents a delayed profile; the whole curve is shifted down and to the right, 
indicating a slower drug release with a lower overall percentage release in the 
time studied. It appears to be a quick release from the beginning up to 10 
minutes reaching almost 50 %, and gradually slows down. The release is 
completed at around 80 minutes with an overall 62 % drug release.   
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                                         Figure 4- 18 Calibration of 5FU 
 
 
 
 
 
 
 
 
 
 
 
Figure 4- 19 Cumulative percentage release of 5FU with and without incorporation of 
FF nanotubes. The blue curve represents free drug release; the red curve represents 
FF tube-bound 5FU release. Data is presented as mean ± SEM (n=3). 
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4.3.5.1 Release model 
As for the mathematical evaluation applied to SA release from FF tubes, 
kinetic models were used to analyze the release profile of 5FU from FF tubes.  
The zero order kinetic model of 5FU release from FF tubes is shown in Figure 
4-20. Since the drug release appeared to be completed at t = 80 minutes, all 
data obtained within 80 minutes was used to generate the fit. A two-phased 
drug release behaviour is apparent in Figure 4-20; the first linear part (red dots) 
is up to 50 % drug release (R2 = 0.987), and the second part (blue points) 
comprises the remaining release up to a final 60 % (R2 = 0.908). The figure 
appears similar to that of the SA release, which also showed a two-phased 
release pattern.  
 
 
 
 
 
 
                 Figure 4- 20 Zero order release model of 5FU from FF tubes. 
 
The first order release model of 5FU released from FF tubes is presented in 
Figure 4-21. The release as described using first order model generates better 
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fit than the zero order model with correlation coefficients of 0.995 and 0.937 
for the two phases, respectively.  
 
 
 
 
 
 
 
            Figure 4- 21 First order release model of 5FU from FF nanotubes. 
 
The release data is also applied to Higuchi model (Figure 4-22). Linear 
progression of the plotted data shows a correlations values of 0.943 for the first 
50 % release and 0.973 for the release between 50 Ð 60 %.  
Finally, the Korsmeyer-Peppas model is presented in Figure 4-23. The drug 
release is considered to be best described using this model as indicated by the 
highest R2 value; linear regression analysis of the data yields the equations of 
best line as y = 0.834x + 0.959 and R2 = 0.993 and y = 0.177x + 1.463 and R2 
= 0.993, where y = LogQ, and x = Logt (Equation 4.4). According to the 
equation, the slope of the line corresponds to the exponent n. Therefore, n = 
0.834 indicates a mixture of Fickian and Case II diffusion kinetics for the first 
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50% drug release; and a second value of n = 0.177 indicating a diffusion that 
may not be described as Fickian.   
  
 
 
 
 
 
                  
                 Figure 4- 22 Higuchi model of 5FU released from FF tubes. 
 
 
 
 
 
 
 
 
           Figure 4- 23 Korsmeyer-Peppas model of 5FU released from FF tubes. 
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A detailed discussion regarding the release mechanisms will be presented later 
in section 4.44. A summary of all models with calculated equation and 
corresponding R2 values is presented in Table 4.2. 
 
              Table 4. 2 Release models and parameters of 5FU/FF nanotubes. 
 
Sample: 5FU incorporated with FF nanotubes 
 
Kinetic 
Model 
 
 
Mathematical 
equation 
 
Calculated equation 
Correlation 
coefficient 
Zero-order Q =Qo + kot 
Q = 6.349 t + 2.959 
Q = 0.298 t +41.35 
0.987 
0.908 
First-order Q = Q∞ (1+e
-k
1
t) 
ln(1-Q/ Q∞)=-0.081t+ 4.587 
ln(1-Q/ Q∞)=-0.006t+ 4.080 
0.995 
 
0.937 
Higuchi Q = kHt 
½ 
Q = 15.95t1/2 Ð 2.682 
Q = 3.442t1/2 + 32.94 
0.943 
0.973 
Korsmeyer
-Peppas 
Q / Q∞ = kt
n 
 
LogQ=0.834Logt+0.959 
LogQ=0.177Logt+1.463 
0.993 
0.993 
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4.4 Discussion 
The work presented in this chapter focuses on the investigation of drug-loaded 
diphenylalanine peptide nanotube and the evaluation of its potential as drug 
carrier for two model drugs: SA and 5FU. The first section deals with the 
successful preparation of drug-nanotube mixtures; different drug 
concentrations and solvents were chosen and SEM characterization was 
performed. The SEM images presented of drug-FF tube samples prepared with 
various drug concentrations and solvents suggest the possible influence of 
these two factors on FF tube self assembly as evident from the change of tube 
morphology with the corresponding change of factors (Figure 4-3, 4-4, and 4-
14). Drug loading analysis was also applied to study the relationship between 
drug loading capacity of FF tube and drug concentration. From the figures 
presented it can be seen that the drug content rapidly increases with initial 
increase of drug concentration, and then stays at the same percentage; further 
concentration increase does not affect the drug loading capacity, which 
suggests a possible saturation loading for each drug (Figure 4-7 and 4-17). 
Furthermore, the UV-Vis spectroscopy spectra of the drug/FF tube (after 
centrifugation, so all loose drugs were removed) show the appearance of both a 
phenylalanine peak at 255/254 nm and peaks of the corresponding drug, which 
again indicate successful drug incorporation (Figure 4-5 and 4-15).  
In vitro release study of the chosen drugs from drug-tube complex using a 
dialysis method was performed in the second section of this chapter; free drug 
release was also conducted for comparison. As presented in the cumulative 
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percentage release figures, both drugs released from the tube show a delayed 
profile and a lowered overall release percentage as compared with the free drug 
release (Figure 4-9 and 4-19). To investigate the kinetics involved in the 
release of each system, four different models were applied and the most suited 
one was Korsmeyer-Papps model for both drugs (as indicated by the highest R2 
value). It is suggested that there might be two different kinetics involved in the 
release of both drugs with the first 50% drug release is governed by a mixture 
of case II transport and Fickian diffusion. A detailed discussion regarding drug 
release mechanism will be presented in a later section (section 4.44). 
 
4.4.1 Influence of drug concentration on diphenylalanine tube 
formation 
The effect of drug concentration on FF tube formation was investigated for 
both SA and 5FU. It should be noted that Ôdrug concentrationÕ does not equate 
to Ôdrug loadingÕ. The result obtained from the drug loading experiment has 
shown that it is a non-linear relationship between drug loading capacity and 
drug concentration.  
The SEM images of FF tubes formed in drug solutions of different 
concentrations suggest an inverse relationship between the tube formation and 
drug concentration; as the drug concentration is increased, fewer tubes are 
observed. This observation may be explained in such a way: If we consider FF 
tube self-assembly process as a nucleation-dependent process [241, 242]; after 
reaching the critical peptide monomer concentration, nanotube self-assembly 
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occurs, the growth of the tube continues until it reaches equilibrium with free 
peptide in solution. Since the equilibrium between peptide monomers and tubes 
is influenced by a number of factors, such as temperature, pH, solvent, addition 
of other ions [105, 106, 114, 243], it is not surprising that the addition of drug 
molecules would disturb the delicate balance between nanotubes and peptide 
monomers (Figure 4-24). 
The precise reason why increased drug concentration would disfavour FF tube 
assembly is not yet understood. As mentioned earlier, it is probably due to 
altering the equilibrium between peptide monomer and assembled nanotube. 
From our data only tentative suggestions can be made based on knowledge of 
the tube structure. It is known that the assembled tubes have a molecular 
structure that comprise 6 FF molecules per turn, which arrange to form an 
inner core composed of hydrophilic peptide bonds and an outer shell composed 
of hydrophobic aromatic groups. The tubes are hence stabilized by a number of 
molecular interactions including π-π interactions between the aromatic groups 
of FF of adjacent β-sheet and inter / intramolecular H-bonding [96]. Therefore, 
any change that disrupts the balance of hydrophobic and electrostatic 
interactions would have an effect on tube structure, directing the equilibrium 
towards the monomer state. SA and 5FU both contain an aromatic ring and 
polar groups such as hydroxyl groups. They are hence good candidates for drug 
incorporation, but also may act as competitors of tube assembly. FF, SA and 
5FU molecules are comparable in terms of molecular weight (i.e. 138, 312 and 
130 g/mol, respectively); all three have flat molecular structures with similar 
functional groups. Although the specific location of binding of these two drug 
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molecules is not known; whether most of them bind to the inner hydrophilic 
channels of the tube or intercalate into the hydrophobic shell remains unclear. 
Nevertheless, it is reasonable to propose that these molecules may interrupt 
tube assembly via a replacement process if present in sufficient quantity. A 
tentative model of drug/FF tube binding is shown in Figure 4-25. Moreover, 
based on this assumption, the difference between the concentration limits 
found for 5FU (0.2mM) and for SA (1mM) may be explained. 5FU molecule 
contains two cyclic amide bonds, which are more polar than the two hydroxyl 
groups presented in the SA molecule. Hence, 5FU would be a better competitor 
against FF in terms of tube formation; tubes are less stable in presence of 5FU 
than SA at the same drug concentration. More investigations are required to 
investigate this model, such as further structural and spectroscopic 
characterization of the tube/drug complex and construction of a 
thermodynamic model of drug loading based on various energy terms are 
needed.         
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Figure 4- 24 Schematic representation of the nucleation-dependent FF tube 
formation. The molecular packing of the tube is shown on the top and a side-view of 
the tube is shown on the right. The black dots and the purple cluster represent the 
water molecules inside of the tube. (The molecular arrangement and tube model are 
adapted from ref. [96]). 
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Figure 4- 25 Schematic representation of drug-loaded diphenylalanine nanotube. The 
drug molecule shown in the figure represents the class of molecules with an aromatic 
ring attached to hydrophilic groups (SA and 5FU both fall into this class). The 
straight lines for simplicity represent peptide bonds and other hydrophilic groups. The 
nanotube is viewed from the top.  
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4.4.2 Influence of solvent on diphenylalanine tube formation 
Ethanol is less polar than water with a dielectric constant of 24.3 at 25 ¡C 
[244]. A number of workers have investigated the effect of ethanol on protein 
folding, showing the ability of ethanol as a disrupting agent through its 
changing of hydration forces and promotion of protein unfolding and 
consequent fibrillization [245-248]. Ethanol has also been applied to pre-
formed amyloid fibrils and shown that high ethanol concentrations at around 
30% can disassemble pre-formed fibrils [249]. Another study performed on 
pre-formed FF peptide nanotubes showed that after the addition of few aliquots 
of pure ethanol, FF tubes disappeared under optical microscopy. This 
disappearance was accompanied by an increase of FF peptide concentration 
suggesting dissolution of the FF nanotubes [250]. The work presented in this 
chapter is consistent with these findings. The introduction of ethanol as a co-
solvent affects the tube formation as reflected in the SEM images; at 40% v/v 
(i.e. ethanol/water = 2:3) or above, no tubes were observed. Furthermore, the 
percentage of ethanol/water seems to play an important role regarding the 
morphology of the assembled structures. SEM images of the samples prepared 
in different proportions of ethanol, show that the morphology of the assemblies 
changes from thin fibrils to tubes with a wider diameter and longer length. This 
further supports previous published results: introducing ethanol to FF tube 
suspension as a co-solvent reduces the polarity of the solution. As a result, this 
weakens hydrophobic interactions and hydrogen bonding, leading to reduced 
tube formation. If substantial amounts of ethanol are applied, this may 
destabilize tube formation. Less ethanol may not be sufficient to dissolve pre-
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formed tubes, but still affect the morphology of the assemblies resulting in 
thinner and shorter fibrils are formed compared to the native FF nanotubes (as 
presented in Figure 4-4). 
    
4.4.3 Relationship between drug loading capacity and drug 
concentration 
The drug loading capacity of FF tube was investigated as a function of drug 
concentration. It is found that the drug content increases with increased 
concentration for both SA and 5FU. The relationship is not directly 
proportional; when SA concentration increases from 0.5mM to 1mM, the drug 
loading varies little from 3.67% to 4.00%; when 5FU concentration increases 
from 0.4mM to 1mM, the drug loading changes from 3.34% to 3.59%. The 
nonlinear increase of drug content with concentration for both drug models 
may be attributed to the spontaneous deposition of drug molecules into/onto FF 
tubes. As previously mentioned in the result section (section 4.3.1), the 
rationale behind choosing SA and 5FU as candidate drug molecules was 
because of their capability of forming hydrogen bonding and π-π interactions 
with FF nanotubes. The non-proportional drug loading may reflect the 
spontaneous nature of drug-tube interactions. As the drug concentration 
increases, the chance of drug molecules to attach onto/into FF tube is 
increased, but the exact percentage loading content is random. As a result, the 
drug loading percentage may vary from batch to batch even if the 
concentration is kept constant. It is therefore essential to calculate drug loading 
Chapter 4 Diphenylalanine nanotubes as a drug carrier 
  147 
for each experiment for accuracy. The random drug loading found here is 
indeed supported by a number of published studies on other carrier-based 
delivery systems for drugs such as 5FU [251]. For the case of 5FU, a study was 
performed poly (L-glutamic acid) / chitosan microcapsules containing 5FU. 
The percentage drug content was also found to increase nonlinearly with 
increased drug concentration, and spontaneous drug accumulation was 
suggested to be a result of the random hydrogen bonding interactions between 
the drug molecule and the carrier [251]. 
 
4.4.4 Drug release from FF nanotube   
The cumulative percentage release of both SA and 5FU from FF nanotubes 
shows a delayed behaviour as compared with that of the free drug. To further 
analyze the release kinetics, different models were employed. As presented 
from the results, both drug/tube complexes exhibit a biphasic release 
behaviour; the first segment appears to be from the beginning up to ~50% drug 
release (between t = 0 to t = 4 mins for SA, and between t = 0 to t = 6 mins for 
5FU release) and the second phase follows from ~50% to the end of the 
release. The distinct two-phased release pattern displays an apparent break 
point in which the slope clearly changes in all cases; evidently there are two 
separate release kinetics involved in drug/FF tube in vitro dissolution process.  
The biphasic release kinetics observed may result from the complicated nature 
of FF nanotube as drug carrier; it is unlike the common matrix systems such as 
hydrogels as apparent polymer swelling does not occur; it is also different from 
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the non-swelling matrices, because it may present some degrees of polymer 
relaxation during dissolution. Considering a system of drug molecules 
presented in a dry nanotube, three factors need to be taken into consideration: 
firstly, free drug molecules that were not bound to FF tubes have been removed 
by centrifugation (assuming complete removal); secondly, the location of drug-
FF binding is unknown (could be intercalated with the tube or inside of the 
core), and thirdly, the loading is spontaneous as previously discussed. Upon 
contact with the release medium (PBS), the self-assembled FF chains may 
experience some level of microscopic rearrangement and drug dissolution can 
take place. The time required for the rearrangement (tr) and for the drug to 
diffuse out (td) may vary according to different delivery systems. For a system 
with tr that is similar to td, the solvent adsorption does not follow FickÕs law of 
diffusion, thus the release becomes anomalous and is generally considered as a 
mixture of Fickian diffusion and case II transport [252, 253]. From the results 
presented here, anomalous diffusion with a first ordered rate kinetics modulates 
the initial release of both SA and 5FU from FF tubes (as indicated by the 
highest correlation coefficient); from 0 % to ~ 50 %, the diffusion of drug 
molecules and the relaxation rates of FF chains are comparable. The second 
phase presented suggests that the mechanism clearly changes during the course 
of delivery for both drugs. It is difficult to find the best model that fits the 
second phase release; the correlation coefficient values of all models applied 
are low. The Korsmeyer model shows that the exponent value n are less than 
0.45 for both systems (0.282 for SA and 0.177 for 5FU), indicating the release 
is an almost-Fickian diffusion as the lowest n value for a Fickian diffusion is 
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0.45 in theory. Various drug delivery systems with a diffusion exponent value 
that is less than 0.45 are found to be common and have been largely reported to 
date [254, 255].  The release is generally described as Ôquasi Fickian diffusionÕ. 
The suggestive causes are varied according to different systems but usually 
comprise unavoidable experimental errors. Nevertheless, Fikian and quasi-
Fickian diffusions are considered to be similar in nature, the rationale behind 
these processes are treated as identical. In the present study, the second phase 
release is sustained as compared to the first phase and is found to be a quasi-
Fickian diffusion. The change of release mechanism could be resultant from 
tube stabilization, i.e. the microscopic rearrangement of FF chains may slow 
down after a period of relaxation, so the time it takes for further chain 
rearrangement is longer. In which case, tr becomes greater than td from 50% to 
60% drug release, which indicates FF chain relaxation outweighs the drug 
diffusion, therefore drug release is slowed down the solvent adsorption with a 
constant diffusitivity takes place. 
The Ôbiphasic release behaviourÕ has been observed in various delivery systems 
from published papers [256-258]. The exact cause of the study presented here 
is unknown. It could be due to a number of factors, such as the random drug 
distribution, which is well known to heavily affect drug release kinetics for 
other delivery systems [259-261]. Additionally, drug molecules that bound to 
the tube surface may diffuse at a faster rate than those bind to the interior core 
of the tube, which may give rise to a burst effect in the release profile followed 
by a slower release.      
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4.5 Conclusions 
The work presented in this chapter is an evaluation of the potential of 
diphenylalanine peptide (FF) nanotube in drug delivery as a drug carrier. 
Successful synthesis of two model drug, salicylic acid (SA) and 5-fluorouracil 
(5FU) loaded FF tubes in various drug concentration and solvents has been 
demonstrated and characterized by SEM imaging, which has shown FF 
nanotube self-assembly is a drug concentration and solvent type dependent 
process. Other characterizations using a combination of UV-Vis spectroscopy 
and XRPD have shown similar molecular packing arrangement between drug-
loaded and native FF tubes. The drug loading capacity of FF tubes showed an 
indirect relationship with the drug concentration, which has indicated a 
spontaneous random binding between FF tube and drug molecules. Finally, in 
vitro release experiment of both drugs from FF tubes were performed and 
compared to that of the bare drug. Extended release profiles have been 
achieved in both cases with an initial phase controlled by a mixture of Fickian 
and case II diffusions. 
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Chapter 5 General Conclusions and Future Directions 
 
The work presented in this thesis has focussed on a dipeptide, diphenylalanine 
(FF), which is the core-recognition motif of βÐamyloid polypeptide. Beside the 
key role it plays in βÐamyloidogenesis, FF has attracted interest in 
nanotechnology due to the physical and chemical stability and mechanical 
rigidity of the self-assembled nanotube form of the peptide. A number of 
promising applications of FF nanotubes have been previously explored. 
However, the work presented here has provided new insights to this area: a 
comparative characterization of FF nanotubes prepared by different methods 
has shown the diversity in tube morphology observed, which has led to the 
suggestion of the mechanism of FF tube self-assembly. Furthermore, 
successful synthesis has been applied to form drug-loaded nanotubes. The 
investigation of the potential of FF tubes as a drug carrier in drug delivery has 
shown promising result of extended drug release, particularly for 5FU 
dissolution. Taken together, pivotal to this work is to provide more knowledge 
of FF peptide nanotubes from both physical and biological prospects.  
In the introductory chapter of this work, an overview of the current 
understanding of FF assembly, characterization and properties has been 
presented. The assembled FF-based nanostructures, together with applications 
in the areas of both non-biological and biological have been introduced. The 
closing of the first chapter has presented the aim and objectives of this thesis. 
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The first experimental study presented in Chapter 2 addressed the self-
assembled FF nanotubes by different methods of preparation. Although this 
dipeptide has been extensively studied for its chemical and physical properties, 
no such parallel comparative investigations have been carried out on the 
formed tubes prepared using different methods. The work presented here for 
the first time evaluated the differences found regarding the physicochemical 
properties of FF tubes of different types of preparation utilizing a number of 
techniques such as atomic force microscopy (AFM), scanning electron 
microscopy (SEM), Raman spectroscopy and x-ray powder diffraction 
(XRPD). The tubes assembled in water alone at 65 ¡C displayed long, straight 
and unbranched morphologies that are in agreement with those previously 
observed by SEM; the ones formed in the mixture of 1,1,1,3,3,3-
hexafluoropropan-2-ol and water appeared differently. Apart from the 
dissimilarities in morphology observed, variation of the size distribution 
performed on large number of tubes was also revealed. These findings led to 
the suggestion of the differences in the mechanisms of tube growth under 
different conditions, but that the endpoint in terms of molecular architecture is 
the same as revealed by XRPD. To further investigate the nucleation and 
growth of FF nanotube self-assembly in the future, selective photosensitizer 
molecules (e.g. 4-acetylbiphenyl and benzophenone) and lanthanide ions 
(which are luminescent materials widely used in optoelectronics such as laser) 
could be chosen to incorporate into the tube assembly. The formation and 
growth of the tubes could be studied by time lapse optical microscopy with a 
filtered UV illumination. Indeed, a recent study has successfully incorporated 
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lanthanide ions such as terbium and europium with FF tube and produced 
photoluminescent peptide nanotubes [131, 132, 134].  
Some of the criteria that must be fulfilled before evaluating the applications of 
FF nanotube in the pharmaceutical field are biocompatibility and 
biodegradability. Other material-based drug delivery systems, such as many 
types of synthetic polymer-based materials have restricted applications because 
of the immunogenic reactions from the body as a result of the questionable 
biodegradability. FF-based nanostructures present several advantages such as 
ease to fabricate with low cost, and biocompatibility and biodegradability. 
Studies have shown that FF nanotubes can easily be degraded by proteolytic 
enzymes such as proteinase K, which is also an essential step in metal 
nanowire fabrication. The expected biocompatibility of FF nanotubes, 
however, has little published information; limited cell-based work has been 
carried out to investigate the biological properties of FF nanotubes. Therefore 
it is crucial to have an improved understanding of FF nanotube cytotoxicity. 
The experiments within Chapter 3 have focused on the biological properties of 
FF nanotubes; the cytotoxicity has been assessed on a HeLa cell line using a 
MTT colorimetric assay. Different factors that may influence the cytotoxicity 
have also been investigated, including different methods of preparation, 
peptide concentration, nanotube solution concentration, presence of HFIP that 
is known to be a cytotoxic solvent, and presence of serum in cell culture 
medium. The results have shown that the tubes prepared by both methods did 
not cause toxicity related damage to HeLa cells at different peptide 
concentration (10 µg/ml and 1000 µg/ml), and at different dilution of pre-
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formed tube suspension (from 1000 µg/ml to 31.65 µg/ml). The toxic HFIP 
was removed by evaporation of HFIP/water mixture at 65 ¡C overnight. HFIP 
on its own has shown a highly toxic effect on HeLa cells with over a 90 % 
decrease in cell metabolic activity. Finally, serum was found to have a 
protective effect on the cells. Cells had a greater metabolic activity and the 
toxicity caused by HFIP was reduced when in presence of serum. Moreover, 
cells in a nanotube-culture medium suspension were studied by total internal 
reflection microscopy and successful images of time-lapse study were captured 
to show the presence of nanotubes inside the cells. Although the specific 
cellular uptake pathway is yet to be determined, based on the size of the tubes 
found, macropinocytosis is the suggested uptake pathway. Whilst cell-based 
studies cannot necessarily be extended to the in vivo case, these observations 
clearly do not rule out the potential applications of FF nanotubes to the 
pharmaceutical and biomedical areas. In the future, more cell lines and more 
cytotoxicity assays (such as neutral red uptake and lactate dehydrogenase 
release assay) could be performed to fully evaluate the cytotoxic property of 
FF nanotubes. Moreover, considering the size of an average cell that ranges 
from few microns to around 100 microns, nanotubes with lengths that are less 
than 100 µm are particularly of interest for applications such as potential drug 
carriers (as presented in Figure 3-10, small tubes inside of HeLa cells were also 
observed from TIRM images; furthermore the time lapse TIRM video provided 
in the Appendix B also showed the movement of short tubes acrossing HeLa 
cell membrane). Based on these considerations, more knowledge regarding the 
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cytotoxicity property of short tubes is needed to further explore the potential of 
FF tubes in biological and pharmaceutical applications.    
Based on the results obtained from the previous two chapters, which have 
provided improved knowledge in terms of the physicochemical and 
cytotoxicity of FF nanotubes, Chapter 4 investigated FF nanotubes as carriers 
in drug delivery. The studies presented in Chapter 4 can be categorized into 
two sections: first involves the synthesis and characterization of drug-loaded 
FF tube complex, next is the evaluation of drug release from nanotubes 
utilizing an in vitro dissolution experiment. 
Two model drugs were selected based on careful considerations: salicylic acid 
(SA) and 5-fluorouracil (5FU); both of which have been well studied and have 
a structure of a planar aromatic ring linked with functional groups such as 
hydroxyl and amide groups that are capable to form hydrogen bonding and 
aromatic interactions with FF nanotube. The preparation was simply achieved 
by mixing pre-formed FF tube solution with drug solution. The relatively 
stratight forward synthesis presents the advantage of FF nanotube-based drug 
delivery system in terms of ease production with low cost. Characterization of 
drug-loaded FF nanotubes using SEM has revealed a morphological change of 
the assemblies as a consequence of varying drug concentrations and solvent 
mixtures. Conjecture of the rationale behind it was made, in which FF self-
assembly is considered as a dedicate equilibrium process between monomer 
concentration and tube formation. Factors that disturb the interactions involved 
in tube assembly may influence the tube formation and also the stability of the 
formed tubes. This suggestion is consistent with published work on FF 
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nanotubes. To further study the physical properties of drug-loaded FF tubes, 
more characterizations are needed. For example, FIB-SEM could be applied to 
cut drug-loaded FF tubes in cross sections. Chemical/elemental 
characterization such as energy-dispersive X-ray spectroscopy could be 
performed to analyze the location of drug molecules.   
In the final experiment discussed in this thesis the potential to utilize FF 
nanotube as drug carrier was evaluated. In vitro drug release studies of drug-
loaded FF were carried out; the release profile was compared with that of the 
bare drug. Controlled drug release with a good overall release reaching over 60 
% was observed for both models. Different kinetic models were applied to 
analyze the release kinetics and the best release mechanism was found by 
fitting the experimental data into different mathematical equations of each 
model. The results have shown that the release of both drugs exhibited a two-
phased release pattern which clearly indicated a change of kinetics during the 
course of delivery. The biphasic release behaviour has been previously 
reported for a number of drug delivery systems. The results analysed using the 
Korsmeyer-Peppas model have revealed that the system follows a first order 
release that was modulated by a mixture of Fickian diffusion and case II 
transport; the latter phase could not be summarized using any existing 
knowledge due to the experimental exponent value lower than the theoretical 
value. Nevertheless, this phenomenon has also been reported for a number of 
drug delivery systems. In the future, more release studies are needed in order to 
fully understand FF nanotube based drug delivery systems. As previously 
discussed, different sized tubes could be introduced to study the effect of tube 
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length on drug release. Furthermore, different pH could also be applied. The 
pH used in the present study was neural (pH = 7.4); it would be interesting to 
investigate the release of drug in a simulated gastric acid medium. 
In conclusion, the results presented throughout this thesis have provided 
information of the physicochemical and biological properties of self-
assembling FF nanotubes; with the addition of the potential of FF nanotubes as 
drug carrier. Based on the knowledge presented in this thesis FF nanotubes 
offered promising potentials in the applications of nanofabrication and drug 
delivery as novel drug carriers.    
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Appendix A 
Diphenylalanine nanotube production yield calculation 
 
The percentage nanotube production is calculated in such a way: freshly 
prepared nanotube suspensions were evaporated overnight at 65 ¡C in an oven. 
The collected solid at the end of the process was mixed with ddH2O and 
centrifuged for 5 minutes at 10,000 rpm. The supernatant was removed after 
centrifugation and the purified nanotubes were again evaporated and weighed. 
The yield of production was calculated by dividing the weight of purified 
nanotubes by the total weight of FF peptide used. The calculation was repeated 
three times and data is presented as mean±SEM. 
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Appendix B 
 
Animations 
 
The video on the enclosed CD contains high-speed time-lapse sequence of 
TIRM images of HeLa cells exposed to FF nanotube suspension (1000 µg/ml). 
To view the animation, copy and paste file to Desktop and open.   
 
 
 
 
 
 
 
